<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Molecular‐targeted first‐line therapy for advanced gastric cancer - Song, H - 2016 | Cochrane Library</title> <meta content="Molecular‐targeted first‐line therapy for advanced gastric cancer - Song, H - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011461.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Molecular‐targeted first‐line therapy for advanced gastric cancer - Song, H - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011461.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011461.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Molecular‐targeted first‐line therapy for advanced gastric cancer" name="citation_title"/> <meta content="Huan Song" name="citation_author"/> <meta content="Karolinska Institutet" name="citation_author_institution"/> <meta content="huan.song@ki.se" name="citation_author_email"/> <meta content="Jianwei Zhu" name="citation_author"/> <meta content="Shandong Provincial Hospital Affiliated to Shandong University" name="citation_author_institution"/> <meta content="DongHao Lu" name="citation_author"/> <meta content="West China Second University Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD011461.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/07/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011461.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011461.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011461.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adenocarcinoma [*drug therapy, mortality, pathology]; Angiogenesis Inhibitors [therapeutic use]; Disease-Free Survival; ErbB Receptors [antagonists &amp; inhibitors]; Esophageal Neoplasms [*drug therapy, mortality, pathology]; *Esophagogastric Junction; Molecular Targeted Therapy [adverse effects, *methods]; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2 [antagonists &amp; inhibitors]; Stomach Neoplasms [*drug therapy, mortality, pathology]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011461.pub2&amp;doi=10.1002/14651858.CD011461.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="f00EizoA";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011461\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011461\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ms","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011461.pub2",title:"Molecular\\u2010targeted first\\u2010line therapy for advanced gastric cancer",firstPublishedDate:"Jul 19, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=f00EizoA&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011461.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011461.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011461.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011461.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011461.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011461.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011461.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011461.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011461.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011461.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2652 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011461.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-sec-0087"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-sec-0029"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-sec-0030"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-sec-0081"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/appendices#CD011461-sec-0092"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/table_n/CD011461StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/table_n/CD011461StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Molecular‐targeted first‐line therapy for advanced gastric cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/information#CD011461-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Huan Song</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/information#CD011461-cr-0003">Jianwei Zhu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011461.pub2/information#CD011461-cr-0004">DongHao Lu</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/information/en#CD011461-sec-0099">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 July 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011461.pub2">https://doi.org/10.1002/14651858.CD011461.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011461-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011461-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011461-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011461-abs-0009">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011461-abs-0001" lang="en"> <section id="CD011461-sec-0001"> <h3 class="title" id="CD011461-sec-0001">Background</h3> <p>Gastric cancer is the fifth most common cancer and third leading cause of cancer‐related deaths worldwide. Complete resection of the whole tumor remains the only approach to treat this malignant disease. Since gastric cancer is usually asymptomatic in its early stages, many people are diagnosed at an advanced stage when the tumor is inoperable. In addition, because other conventional treatments (radiotherapy and chemotherapy) have only modest efficacy for those with advanced/metastatic gastric cancer, the prognosis in such cases is poor. Recently, trials have provided some promising results regarding molecular‐targeted therapy, raising the possibility that the development of these agents could be a fruitful approach. However, the benefit of molecular‐targeted therapy for advanced gastric cancer remains inconclusive. </p> </section> <section id="CD011461-sec-0002"> <h3 class="title" id="CD011461-sec-0002">Objectives</h3> <p>To evaluate the efficacy and safety of molecular‐targeted therapy , either alone or in combination with chemotherapy, in people with advanced gastric cancer. </p> </section> <section id="CD011461-sec-0003"> <h3 class="title" id="CD011461-sec-0003">Search methods</h3> <p>We searched the following databases (from inception to December 2015): the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and CINAHL. In addition, we searched the reference lists of included trials and contacted experts in the field. </p> </section> <section id="CD011461-sec-0004"> <h3 class="title" id="CD011461-sec-0004">Selection criteria</h3> <p>We searched for randomized controlled trials (RCTs) in adults (aged 18 years or older) with histologically‐confirmed advanced adenocarcinoma of the stomach/gastro‐esophageal junction. Trials of participants with esophageal adenocarcinoma were also considered to be eligible. The eligible trials should aim to evaluate the effects of molecular‐targeted agents on participants' prognosis. </p> </section> <section id="CD011461-sec-0005"> <h3 class="title" id="CD011461-sec-0005">Data collection and analysis</h3> <p>Two review authors independently performed selection of eligible trials, assessment of trial quality, and data extraction. We used methods of survival analysis and expressed the intervention effect as a hazard ratio (HR) when pooling time‐to‐event data, and calculated the odds ratio (OR) for dichotomous data and mean differences (MDs) for continuous data, with 95% confidence intervals (CI). </p> </section> <section id="CD011461-sec-0006"> <h3 class="title" id="CD011461-sec-0006">Main results</h3> <p>We included 11 studies randomizing 4014 participants to molecular‐targeted therapy plus conventional chemotherapy or chemotherapy alone. Five were at low risk of bias, and we considered the risk of bias in the other six studies to be high, mainly due to their open‐label design. All identified studies reported data regarding survival. We found low‐quality evidence that molecular‐targeted may have a small effect on mortality (HR 0.92, 95% CI 0.80 to 1.05, 10 studies) compared with conventional chemotherapy alone. Similarly, it may have little effect on progression‐free survival when compared with conventional chemotherapy alone (HR 0.90, 95% CI 0.78 to 1.04, 11 studies; low‐quality evidence). We did not find evidence from subgroup analysis that survival outcomes differed by type of molecular‐targeted agent (EGFR‐ or VEGF‐targeting agents) or tumor type, meaning that we were unable to explain the variation in effect across the studies by the presence or absence of prognostic biomarkers or type of molecular‐targeted agent. From 11 eligible trials, we were able to use data from 3723 participants with measurable tumors. We found low‐quality evidence that molecular‐targeted therapy may increase tumor response (OR 1.24, 95% CI 1.00 to 1.55, low‐quality evidence). Data from one small trial were too limited to determine the effect of treatment on quality of life (very low‐quality evidence). The addition of targeted therapy to chemotherapy probably increases the risk of adverse events (OR 2.23, 95% CI 1.27 to 3.92, 5 trials, 2290 participants, moderate‐quality evidence) and severe adverse event (OR 1.19, 95% CI 1.03 to 1.37, 8 trials, 3800 participants), compared with receiving chemotherapy alone. </p> </section> <section id="CD011461-sec-0007"> <h3 class="title" id="CD011461-sec-0007">Authors' conclusions</h3> <p>There is uncertainty about the effect of adding targeted therapy to chemotherapy on survival outcomes in people with advanced gastric cancer, with very little information on its impact on quality of life. There is more certain evidence of increased risk of adverse events and serious adverse events. The main limitation of the evidence for survival outcomes was inconsistency of effects across the studies, which we could not explain by prespecified subgroups in terms of the type of therapy or tumor type. Ongoing studies in this area are small and unlikely to improve our understanding of the effects of targeted therapy, and larger studies are needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011461-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011461-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011461-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011461-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011461-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011461-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011461-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011461-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011461-abs-0003" lang="en"> <h3>Effect of molecular‐targeted therapy on the progress and survival of people in the late stages of stomach cancer </h3> <p><b>Review question</b> </p> <p>Does molecular‐targeted therapy (a type of treatment specifically targeting cancer cells) benefit people with late‐stage stomach cancer? </p> <p><b>Background</b> </p> <p>Due to the lack of clinical symptoms, many stomach cancers are diagnosed at a very late stage (stage III or stage IV), for which surgery cannot be the best option anymore. The effects of chemotherapy and radiotherapy on late‐stage stomach cancer are very limited, leading to a low possibility of survival for people with the disease (fewer than one in five people survive for longer than five years). Recent research suggested that molecular‐targeted therapy may prolong the survival time for people with late‐stage stomach cancer. However, the therapeutic benefit of this treatment is still under debate. </p> <p><b>Study characteristics</b> </p> <p>We searched databases until December 2015 for randomized controlled trials (clinical trials where people are randomly allocated to one of two or more treatment groups) in adults (aged 18 years or over), diagnosed with late‐stage stomach cancer. We found 11 trials (4014 participants) that met our selection requirements and randomized people to receive targeted treatment plus chemotherapy or chemotherapy alone. </p> <p><b>Key results</b> </p> <p>Adding molecular‐targeted treatment to chemotherapy may have a small effect on survival and on stopping further development of the disease, compared with chemotherapy alone, but the evidence is of low quality. The treatment may increase the likelihood that tumors get smaller (low‐quality evidence), but there is insufficient evidence to know how much of a difference it can make to the person's quality of life (very low‐quality evidence). It probably increases the risk of adverse events and serious adverse events (moderate‐quality evidence). </p> <p><b>Quality of the evidence</b> </p> <p>Currently, the evidence is of low quality for survival outcomes, mainly due to the type of study design, and the inconsistencies between the results of individual studies. We therefore suggest that well‐designed clinical trials should be performed, to improve the evidence base. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011461-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011461-sec-0087"></div> <h3 class="title" id="CD011461-sec-0088">Implications for practice</h3> <section id="CD011461-sec-0088"> <p>There is uncertainty about the effect of adding targeted therapy to chemotherapy on survival outcomes in people with advanced gastric cancer, with very little information available on their quality of life. The main limitation of the evidence for survival outcomes was inconsistent effects across the studies, which we could not explain by prespecified subgroups in terms of the type of therapy or tumor type. There is more certain evidence of an increased risk of adverse events. </p> </section> <h3 class="title" id="CD011461-sec-0089">Implications for research</h3> <section id="CD011461-sec-0089"> <p>Most of the ongoing studies we found are Phase II clinical trials with a limited number of participants. We would therefore expect that they are unlikely to provide enough evidence for us to further our understanding. In view of the high levels of inconsistency across the studies, further studies would need to explore the relationship between selection of participants and the type of targeted therapy. Randomized controlled trials should maintain blinding of outcome assessors. Study conduct should be independent, i.e. data analysis and results interpretation to be conducted only by statisticians and researchers not employed by sources of commercial sponsorship. </p> <p>Studies should report adverse events with summary data, and measure quality of life. Focusing recruitment of study populations based on our subgroup analyses would also help to establish whether there are any survival differences between participants with different tumor types. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011461-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011461-sec-0015"></div> <div class="table" id="CD011461-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: Molecular‐targeted therapy plus chemotherapy compared to chemotherapy alone for people with advanced gastric cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Molecular‐targeted therapy plus chemotherapy compared to chemotherapy alone for people with advanced gastric cancer </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced gastric cancer<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> molecular‐targeted therapy plus chemotherapy<br/> <b>Comparison:</b> chemotherapy alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with chemotherapy alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with molecular‐target therapy plus chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population:12 month mortality rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.92</b> <br/> <b>(0.80 to 1.05)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3843 participants</p> <p>(10 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Assumed risk calculated based on 12 months overall mortality rates (extracted from corresponding Kaplan‐Meier curves) observed in the control arms of the included trials (53.6%). </p> <p>We could not explain variation in the effect by subgroup analyses examining the type of molecular targeted agent or tumour type. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>536 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>507 per 1000<br/> (459 to 553) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population: 6 month progression‐free survival rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.90</b> <br/> <b>(0.78 to 1.04)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4014 participants</p> <p>(11 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Assumed risk calculated based on 6‐month progression rate (extracted from corresponding Kaplan‐Meier curves) observed in the control arms of the included trials (55.5%) </p> <p>We could not explain variation in the effect by subgroup analyses examining the type of molecular targeted agent or tumour type. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>555 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>517 per 1000<br/> (432 to 577) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> (change from baseline in EORTC QOL30 global health status scale) </p> <p>Duration of follow‐up: Median follow‐up differed between treatment groups (28 months with molecular‐targeted therapy and 23 months in control group) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Higher change scores were obtained for chemotherapy‐alone group (MD 10 ± 33.9 SD) than molecular‐targeted therapy plus chemotherapy group (MD 0.0 ± 28.1 SD), but the results are based on a very small number of participants and the confidence interval is wide </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 participants</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>5,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall response rate</b> </p> <p>Duration of follow‐up: varied considerably between studies (the median follow‐up time ranged from 5.3 months to 28.5 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.24</b> <br/> <b>(1.00 to 1.55)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3723<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>365 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>417 per 1000<br/> (365 to 472) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse event (any)</b> </p> <p>Duration of follow‐up: varied considerably between studies (the median follow‐up time ranged from 5.3 months to 28.5 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 2.23</b> <br/> <b>(1.27 to 3.92)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2290<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>962 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>983 per 1000<br/> (971 to 990) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Severe adverse event (grade ≥ 3 )</b> </p> <p>Duration of follow‐up: varied considerably between studies (the median follow‐up time ranged from 5.3 months to 28.5 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.19</b> <br/> <b>(1.03 to 1.37)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3800<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>669 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>707 per 1000<br/> (676 to 735) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; <b>HR</b>: Hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to imprecision: the confidence interval obtained under both the primary and sensitivity analysis for risk of bias includes potentially meaningful differences with either intervention. </p> <p><sup>2</sup>Downgraded one level due to inconsistency: The size and direction of effect varied across the studies (significant heterogeneity was detected). </p> <p><sup>3</sup>Removal of studies at high risk of performance bias reduced the statistical heterogeneity and increased the effect size, so we did not downgrade for risk of bias. </p> <p><sup>4</sup>Downgraded one level due to imprecision: the confidence interval around the effect includes both meaningful benefit and little or no effect of molecular‐targeted therapy. </p> <p><sup>5</sup>Downgraded two levels due to imprecision: effect was estimated based on results from 53 participants and the confidence interval includes appreciable harm and little/no effect. </p> <p><sup>6</sup>Downgraded one level due to serious risk of bias: open‐label study was at high risk of performance bias for this outcome. </p> <p><sup>7</sup>Downgraded one level due to risk of bias (selective reporting bias): three included studies did not provide data on this outcome, and three others had no summary data for meta‐analysis. </p> <p><sup>8</sup>Downgraded one level due to risk of bias (performance bias): removing studies at high risk bias due to lack of blinding resulted in a more imprecise effect suggesting that the results may have been sensitive to the exclusion of open‐label studies. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011461-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011461-sec-0016"></div> <section id="CD011461-sec-0017"> <h3 class="title" id="CD011461-sec-0017">Description of the condition</h3> <p>Gastric cancer is the fifth most common cancer and third leading cause of cancer‐related deaths worldwide (<a href="./references#CD011461-bbs2-0037" title="FerlayJ , SoerjomataramI , DikshitR , EserS , MathersC , RebeloM , et al. Cancer incidence and mortality worldwide: sources, methods and major patterns inGLOBOCAN 2012. International Journal of Cancer2015;136(5):E359‐86. ">Ferlay 2015</a>). The incidence of gastric cancer has been shown to have declined in many developed countries. However, in recent years the decline appears to be slowing in both men and women. In Sweden, there has been an increased prevalence of atrophic gastritis, a well‐established precancerous lesion of non‐cardia gastric cancer, among young middle‐aged residents (<a href="./references#CD011461-bbs2-0063" title="SongH , HeldM , SandinS , RautelinH , EliassonM , SöderbergS , et al. Increase in the prevalence of atrophic gastritis among adults age 35 to 44 years old in Northern Sweden between 1990 and 2009. Clinical Gastroenterology and Hepatology2015;13(9):1592‐600. ">Song 2015a</a>). In addition, based on USA cancer register data, there has been an increase in the incidence of non‐cardia gastric cancer in the white population aged 25 to 39 years (<a href="./references#CD011461-bbs2-0029" title="AndersonWF , CamargoMC , FraumeniJFJr , CorreaP , RosenbergPS , RabkinCS . Age‐specific trends in incidence of noncardia gastric cancer in US adults. JAMA2010;303(17):1723‐28. ">Anderson 2010</a>). These recent trends indicate that the etiology of this malignancy may be changing. </p> <p>Complete resection of the whole tumor remains the only approach to treat this malignant disease. Evidence shows that additional perioperative chemotherapy or adjuvant chemotherapy increases the chance of survival (40% five‐year survival rate) (<a href="./references#CD011461-bbs2-0052" title="MacdonaldJS , SmalleySR , BenedettiJ , HundahlSA , EstesNC , StemmermannGN , et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New England Journal of Medicine2001;345(10):725‐30. ">Macdonald 2001</a>; <a href="./references#CD011461-bbs2-0061" title="SakuramotoS , SasakoM , YamaguchiT , KinoshitaT , FujiiM , NashimotoA , et al. Adjuvant chemotherapy for gastric cancer with S‐1, an oral fluoropyrimidine. New England Journal of Medicine2007;357(18):1810‐20. ">Sakuramoto 2007</a>). However, since gastric cancer is usually asymptomatic in its early stages, many people are diagnosed at an advanced stage, when the tumor is inoperable. In addition, because other conventional treatments (radiotherapy and chemotherapy) have only modest efficacy for those with advanced/metastatic gastric cancer, the prognosis in such cases is poor; the five‐year survival rate is less than 10% (<a href="./references#CD011461-bbs2-0058" title="PowerDG , KelsenDP , ShahMA . Advanced gastric cancer‐‐slow but steady progress. Cancer Treatment Reviews2010;36(5):384‐92. ">Power 2010</a>), and the median survival time in the range of 6 to 11 months (<a href="./references#CD011461-bbs2-0071" title="WagnerAD , UnverzagtS , GrotheW , KleberG , GrotheyA , HaertingJ , et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews2010, Issue 3. [DOI: 10.1002/14651858.CD004064.pub3] ">Wagner 2010</a>). </p> <p>It has been shown that chemotherapy improves quality of life and prolongs survival when compared to best supportive care (BSC) alone (<a href="./references#CD011461-bbs2-0069" title="WagnerAD , GrotheW , HaertingJ , KleberG , GrotheyA , FleigWE . Chemotherapy in advanced gastric cancer: a systematic review and meta‐analysis based on aggregate data. Journal of Clinical Oncology2006;24(18):2903‐9. ">Wagner 2006</a>). Combination chemotherapy, usually comprising fluorouracil (or its oral prodrugs) plus a platinum compound (e.g. cisplatin), with or without the addition of a third drug (typically docetaxel or epirubicin), is currently the standard first‐line regimen for advanced gastric cancer (AGC) (<a href="./references#CD011461-bbs2-0059" title="PriceTJ , ShapiroJD , SegelovE , KarapetisCS , PavlakisN , VanCutsemE , et al. Management of advanced gastric cancer. Expert Review of Gastroenterology &amp; Hepatology2012;6(2):199‐208. ">Price 2012</a>). However, the responses are usually partial and limited, with considerable toxicities (<a href="./references#CD011461-bbs2-0071" title="WagnerAD , UnverzagtS , GrotheW , KleberG , GrotheyA , HaertingJ , et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews2010, Issue 3. [DOI: 10.1002/14651858.CD004064.pub3] ">Wagner 2010</a>). Also, radiation therapy (RT) is usually reserved only for symptom control in AGC, especially for pain or uncontrolled bleeding. The current limitations in treatment support the need to investigate safer and more effective agents for AGC treatment. </p> <p>See <a href="./appendices#CD011461-sec-0093">Appendix 1</a> for a glossary of topic‐specific terms. </p> </section> <section id="CD011461-sec-0018"> <h3 class="title" id="CD011461-sec-0018">Description of the intervention</h3> <p>With our growing understanding of the underlying molecular basis of carcinogenesis, several targeted agents have been developed, delivering promising outcomes for treating people with lung, colon, breast, or kidney cancer. Nevertheless, compared to other solid tumors which predominantly rely on a particular signal pathway, gastric cancer appears to have a more complicated molecular and genetic carcinogenesis (<a href="./references#CD011461-bbs2-0074" title="WuK , NieY , GuoC , ChenY , DingJ , FanD . Molecular basis of therapeutic approaches to gastric cancer. Journal of Gastroenterology and Hepatology2009;24(1):37‐41. ">Wu 2009</a>). Although it might theoretically limit the application of molecular‐targeted therapy in this field, clinical trials have shown favorable efficacy results when adding a targeted agent (trastuzumab) to standard chemotherapy for human epidermal growth factor receptor‐2 (HER‐2)‐positive people with AGC (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>). Based on this pivotal phase III trial, trastuzumab has been approved as the first targeted agent in the first‐line treatment of people with HER‐2 over‐expressing AGC, both in the European Union (<a href="./references#CD011461-bbs2-0036" title="European Medicines Agency. Herceptin 150 mg powder for concentrate for solution for infusion: summary of product characteristics. www.emea.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/000278/WC500074922.pdf. (Accessed 6 November 2013). ">European Medicines Agency 2013</a>) and in the USA (<a href="./references#CD011461-bbs2-0038" title="GenentechInc . Herceptin (trastuzumab): US prescribing information 2010. www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5256lbl.pdf. (Accessed 6 November 2013). ">Genentech 2013</a>). More recently, lapatinib plus paclitaxel has also been shown to produce a higher overall response rate compared to paclitaxel alone as the second‐line treatment for HER‐2‐positive AGC, although the improvement in survival time was not statistically significant (11 months versus 8.9 months, P = 0.10) (<a href="./references#CD011461-bbs2-0016" title="SatohT , DoiT , OhtsuA , TsujiA , OmuroY , MukaiyamaA , et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second‐line treatment of HER2‐amplified advanced gastric cancer in Asian populations: TyTAN ‐ A randomized, phase III study. Journal of Clinical Oncology2014;32(19):2039‐49. ">Satoh 2014</a>). Additional clinical evidence continues to emerge regarding novel agents targeting other signaling pathways. With minor toxicity (e.g. acne‐like rash or diarrhea) (<a href="./references#CD011461-bbs2-0072" title="WidakowichC , DeCastroGJr , DeAzambujaE , DinhP , AwadaA . Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist2007;12(12):1443‐55. ">Widakowich 2007</a>), use of molecular‐targeted agents alone or together with standard chemotherapy could be a rational approach to better outcomes for people with AGC. </p> <p>Briefly, most targeted therapies for AGC focus on vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) pathways. Compounds targeting other pathways, such as PI3K/mTOR and HGF/MET, are also under investigation, but mainly in Phase I and Phase II clinical evaluations. The targeted agents under development are listed and summarized in <a href="#CD011461-tbl-0002">Table 1</a>. </p> <div class="table" id="CD011461-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Molecular‐targeted agents for advanced gastric cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Molecular target</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Mechanism of action</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Targeted agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase of development</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>EGFR‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p>Anti‐EGFR mAb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cetuximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Panitumumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p>EGFR TKIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erlotinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gefitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Anti‐HER‐2 mAb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trastuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>HER‐2 and EGFR TKI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lapatinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>VEGF‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Anti‐VEGF mAb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Anti‐VEGFR mAb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramucirumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>VEGFR TKI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MTI, targeted on VEGFR, PDGFR and Raf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sorafenib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MTI, targeted on VEGFR, PDGFR and c‐Kit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cediranib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mainly targeted on VEGFR‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apatinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P13K/mTOR‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>mTOR inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>HGF/MET‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p>MET TKI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Foretinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I‐II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crizotinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I‐II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>anti‐MET antibody</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Onartuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>anti‐HGF antibody</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rilotumumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMP‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>MMP inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Marimastat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>FGF‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>FGFR inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZD 4547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>dual inhibitor of FGF and VEGF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brivanib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HDAC‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>HDAC inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vorinostat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I‐II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EpCAM‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Trifuctional bispecific antibody</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Catumaxomab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>EGFR: epidermal growth factor receptor; FGF: fibroblast growth factor; FGFR: fibroblast growth factor receptor; HDAC: histone deacetylase; HGF: hepatocyte growth factor; mAb: monoclonal antibodies; MMP: matrix metalloproteinase; MTI: multi‐targeted TKI; mTOR: mammalian target of rapamycin; PDGFR: platelet derived growth factor receptor; TKI: tyrosine kinase inhibitor; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor </p> </div> </div> </section> <section id="CD011461-sec-0019"> <h3 class="title" id="CD011461-sec-0019">How the intervention might work</h3> <section id="CD011461-sec-0020"> <h4 class="title">EGFR inhibitors</h4> <p>Epidermal growth factor receptor (EGFR) is the cell surface receptor for members of the epidermal growth factor (EGF) family, existing at multiple sites, including skin, gut, and renal tissue. By binding of specific ligands (EGF or transforming growth factor alpha) to its extracellular domain, EGFR can be activated, and thus its intracellular tyrosine kinase domain initiates downstream signals of rat sarcoma (Ras)/rapidly accelerated fibrosarcoma (Raf)/mitogen‐activated protein kinase (MAPK) or the protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) pathway, which eventually lead to DNA synthesis and cell proliferation (<a href="#CD011461-fig-0001">Figure 1</a>). The EGFR family consists of four members: HER‐1 (also know as EGFR), HER‐2, HER‐3, and HER‐4, among which the HER‐1 and HER‐2 represent the targets for current drug development for AGC. </p> <div class="figure" id="CD011461-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Schematic diagram of key signaling pathways in gastric carcinogenesis and the corresponding molecular targeted agents" data-id="CD011461-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Schematic diagram of key signaling pathways in gastric carcinogenesis and the corresponding molecular targeted agents </p> </div> </div> </div> <section id="CD011461-sec-0021"> <h5 class="title">Targeting EGFR (HER‐1)</h5> <p>Studies have shown that the over‐expression of this growth factor receptor is present in 27% to 64% of gastric cancers (<a href="./references#CD011461-bbs2-0045" title="IlsonDH , KelsenD , ShahM , SchwartzG , LevineDA , BoydJ , et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer2011;117(7):1409‐14. ">Ilson 2011</a>; <a href="./references#CD011461-bbs2-0047" title="KimMA , LeeHS , LeeHE , JeonYK , YangHK , KimWH . EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology2008;52(6):738‐46. ">Kim 2008</a>; <a href="./references#CD011461-bbs2-0050" title="LietoE , FerraraccioF , OrdituraM , CastellanoP , MuraAL , PintoM , et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Annals of Surgical Oncology2008;15(1):69‐79. ">Lieto 2008</a>), which might also be associated with more aggressive histology and poorer prognosis. The common approach to inhibit the EGFR is either by blocking the extracellular domain of EGFR via monoclonal antibodies (cetuximab/panitumumab), or inhibiting its intracellular tyrosine kinase domain (erlotinib/gefitinib). Although EGFR tyrosine kinase inhibitors (TKIs) have been demonstrated to be effective in lung cancer treatment, poor efficacy was reported for AGC (<a href="./references#CD011461-bbs2-0035" title="DragovichT , McCoyS , Fenoglio‐PreiserCM , WangJ , BenedettiJK , BakerAF , et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. Journal of Clinical Oncology2006;24(30):4922‐7. ">Draovich 2006</a>). Similarly, a recent trial comparing cetuximab in combination with standard chemotherapy to chemotherapy alone (<a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>) found no significant clinical benefit for the combination treatment. </p> </section> <section id="CD011461-sec-0022"> <h5 class="title">Targeting HER‐2</h5> <p>HER‐2 over‐expression has been observed in approximately 20% of all gastric cancers (<a href="./references#CD011461-bbs2-0048" title="KimKC , KohYW , ChangHM , KimTH , YookJH , KimBS , et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole‐tissue sections and 595 cases of tissue microarrays. Annals of Surgical Oncology2011;18(10):2833‐40. ">Kim 2011</a>; <a href="./references#CD011461-bbs2-0051" title="LordickF . Trastuzumab: a new treatment option for HER2‐positive metastatic gastric and gastroesophageal junction cancer. Future Oncology2011;7(2):187‐99. ">Lordick 2010b</a>; <a href="./references#CD011461-bbs2-0075" title="YanoT , DoiT , OhtsuA , BokuN , HashizumeK , NakanishiM , et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncology Reports2006;15(1):65‐71. ">Yano 2006</a>), with notably higher prevalence in intestinal than in diffuse or mixed gastric cancer (32.2% versus 6.1% or 20.4% respectively) (<a href="./references#CD011461-bbs2-0030" title="BangYJ . Advances in the management of HER2‐positive advanced gastric and gastroesophageal junction cancer. Journal of Clinical Gastroenterology2012;46(8):637‐48. ">Bang 2012</a>). Despite emerging data showing poorer outcomes for people with HER‐2‐positive gastric cancer (<a href="./references#CD011461-bbs2-0031" title="BegnamiMD , FukudaE , FregnaniJH , NonogakiS , MontagniniAL , DaCostaWLJr , et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. Journal of Clinical Oncology2011;29(22):3030‐6. ">Begnami 2011</a>; <a href="./references#CD011461-bbs2-0048" title="KimKC , KohYW , ChangHM , KimTH , YookJH , KimBS , et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole‐tissue sections and 595 cases of tissue microarrays. Annals of Surgical Oncology2011;18(10):2833‐40. ">Kim 2011</a>), the prognostic value of HER‐2 over‐expression in gastric cancer remains a controversial issue (<a href="./references#CD011461-bbs2-0034" title="ChuaTC , MerrettND . Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes‐‐a systematic review. International Journal of Cancer2012;130(12):2845‐56. ">Chua 2011</a>; <a href="./references#CD011461-bbs2-0039" title="GrabschH , SivakumarS , GrayS , GabbertHE , MüllerW . HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value ‐ conclusions from 924 cases of two independent series. Cell Oncology2010;32(1‐2):57‐65. ">Grabsch 2010</a>). Trastuzumab, a humanized recombinant monoclonal antibody that selectively binds to the extracellular domain of HER‐2, when applied together with standard chemotherapy exhibited a superior outcome for people with HER‐2‐positive AGC compared to chemotherapy alone (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>). Apart from directly blocking the HER‐2 signaling pathways and its downstream events, this target agent might also indirectly induce antibody‐dependent cellular cytoxicity (<a href="./references#CD011461-bbs2-0064" title="SpectorNL , BlackwellKL . Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2‐positive breast cancer. Journal of Clinical Oncology2009;27(34):5838‐47. ">Spector 2009</a>). Recently, a dual TKI inhibiting both HER‐2 and EGFR was developed (lapatinib). However, this agent produced disappointing results when applied to people with HER‐2‐negative AGC (<a href="./references#CD011461-bbs2-0046" title="IqbalS , GoldmanB , Fenoglio‐PreiserCM , LenzHJ , ZhangW , DanenbergKD , et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first‐line therapy in patients with advanced or metastatic gastric cancer. Annals of Oncology2011;22(12):2610‐5. ">Iqbal 2011</a>). </p> </section> </section> <section id="CD011461-sec-0023"> <h4 class="title">Angiogenesis inhibitors</h4> <p>Vascular endothelial growth factor (VEGF) is a family of proteins produced by cells that stimulate angiogenesis. As ligands interact with VEGF receptors (VEGFRs) located in the cell surface (see <a href="#CD011461-fig-0001">Figure 1</a>), VEGFs are crucial promotors to mediate endothelial cell proliferation and new vessel formation (<a href="./references#CD011461-bbs2-0033" title="CarmelietP . Angiogenesis in health and disease. Nature Medicine2003;9(6):653‐60. ">Carmeliet 2003</a>). There are four VEGF members (VEGF‐A, VEGF‐B, VEGF‐C, and VEGF‐D) and three types of VEGFRs (VEGFR‐1, VEGFR‐2, and VEGFR‐3). </p> <p>For most solid cancers, both tumor growth and metastasis are highly dependent on misregulated angiogenesis (<a href="./references#CD011461-bbs2-0042" title="HanahanD , FolkmanJ . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell1996;86(3):353‐64. ">Hanahan 1996</a>). Therefore, the VEGF pathway, as a key regulator of angiogenesis, has become a rational target for the development of therapeutic agents. In gastric cancer, the expression of VEGF and VEGFR was found in approximately 40% of patients (<a href="./references#CD011461-bbs2-0053" title="MaedaK , ChungYS , OgawaY , TakatsukaS , KangSM , OgawaM , et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer1996;77(5):858‐63. ">Maeda 1996</a>; <a href="./references#CD011461-bbs2-0055" title="NiXF , WuCP , JiangJT . Serum VEGFR‐3 and survival of advanced gastric cancer patients treated with FOLFOX. World Journal of Gastroenterology2010;16(17):2163‐9. ">Ni 2010</a>). Furthermore, studies revealed that the expression of VEGF was associated with tumor vascularity and metastases, thus indicating a poor prognosis (<a href="./references#CD011461-bbs2-0050" title="LietoE , FerraraccioF , OrdituraM , CastellanoP , MuraAL , PintoM , et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Annals of Surgical Oncology2008;15(1):69‐79. ">Lieto 2008</a>; <a href="./references#CD011461-bbs2-0066" title="TanigawaN , AmayaH , MatsumuraM , ShimomatsuyaT , HoriuchiT , MuraokaR , et al. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Research1996;56(11):2671‐6. ">Tanigawa 1996</a>). </p> <p>Similar to the strategies for EGFR pathways, VEGF‐targeting agents function through neutralizing antibodies to VEGF (bevacizumab), through blocking the extracellular part of its receptor (ramucirumab), or through inhibiting its intracellular tyrosine kinase domain (sunitinib/sorafenib/cediranib/apatinib). Most of the VEGFR TKI agents are actually multi‐targeted TKIs. For example, sorafenib also targets the platelet‐derived growth factor receptor (PDGFR) and RAF pathways. Consequently, sorafenib can theoretically exert antineoplastic action from two different aspects (<a href="./references#CD011461-bbs2-0073" title="WilhelmSM , AdnaneL , NewellP , VillanuevaA , LlovetJM , LynchM . Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics2008;7(10):3129‐40. ">Wilhelm 2008</a>): firstly, it inhibits tumor proliferation by blocking RAF/mitogen‐activated protein kinase (MEK)/extracellular‐signal‐regulated kinases (ERK) signaling pathways; and secondly, it suppresses angiogenesis by blocking VEGR and PDGFR. However, in a Phase II clinical trial, there was no evidence to indicate its superiority over combination chemotherapy for AGC treatment (<a href="./references#CD011461-bbs2-0065" title="SunW , PowellM , O'DwyerPJ , CatalanoP , AnsariRH , BensonAB3rd . Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. Journal of Clinical Oncology2010;28(18):2947‐51. ">Sun 2010</a>). </p> </section> <section id="CD011461-sec-0024"> <h4 class="title">Other targeted agents</h4> <section id="CD011461-sec-0025"> <h5 class="title">Targeting PI3K‐Akt‐mTOR pathway</h5> <p>The mammalian target of rapamycin (mTOR) is a key protein kinase. After being activated by PI3K through Akt, mTOR could mediate signals responsible for cell growth and proliferation, cellular metabolism, and angiogenesis (<a href="./references#CD011461-bbs2-0062" title="ShawRJ , CantleyLC . Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature2006;441(7092):424‐30. ">Shaw 2006</a>). The activity of mTOR could be positively regulated by many receptors, including EGFRs and VEGFRs, and negatively regulated by some intracellular factors, such as phosphatase and tensin homolog (PTEN) (see <a href="#CD011461-fig-0001">Figure 1</a>). Previous research suggests that the PI3K‐Akt‐mTOR pathway is frequently activated in gastric cancer (<a href="./references#CD011461-bbs2-0054" title="MurayamaT , InokuchiM , TakagiY , YamadaH , KojimaK , KumagaiJ , et al. Relation between outcomes and localisation of p‐mTOR expression in gastric cancer. British Journal of Cancer2009;100(5):782‐8. ">Murayama 2009</a>; <a href="./references#CD011461-bbs2-0076" title="YuG , WangJ , ChenY , WangX , PanJ , LiG , et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clinical Cancer Research2009;15(5):1821‐9. ">Yu 2009</a>). Notably, relative to upstream receptors with an over‐expression rate of only 20% to 30%, activated Akt was detected in more than 80% of gastric cancer cases (<a href="./references#CD011461-bbs2-0076" title="YuG , WangJ , ChenY , WangX , PanJ , LiG , et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clinical Cancer Research2009;15(5):1821‐9. ">Yu 2009</a>). It might indicate that inhibitors at the PI3K‐Akt level or mTOR level could be more effective than those targeting upstream moleculars. Currently, everolimus is the most investigated agent particularly targeting mTOR. </p> </section> <section id="CD011461-sec-0026"> <h5 class="title">Targeting HGF/MET</h5> <p>The hepatocyte growth factor receptor (HGF)/MET receptor, together with its ligand hepatocyte growth factor/scatter factor (HGF/SF), mediates the epithelial‐to‐mesenchymal transition (EMT) during embryogenesis, as well as the process of tumor invasion and metastasis. Over‐expression of MET presents in about 50% to 60% of people with gastric cancer (<a href="./references#CD011461-bbs2-0041" title="GrazianoF , GalluccioN , LorenziniP , RuzzoA , CanestrariE , D'EmidioS , et al. Genetic activation of the MET pathway and prognosis of patients with high‐risk, radically resected gastric cancer. Journal of Clinical Oncology2011;29(36):4789‐95. ">Graziano 2011</a>), and its prognostic value remains unclear. Until now, molecular drugs targeting this part include onartuzumab (anti‐MET antibody), rilotumumab (anti‐HGF antibody), foretinib and crizotinib (MET TKIs). </p> </section> <section id="CD011461-sec-0027"> <h5 class="title">Targeting MMPs</h5> <p>Matrix metalloproteins (MMPs) are a family of zinc‐dependent endopeptidases that break down the components of the extracellular matrix. The MMPs play an important role in tissue remodeling through association with various physiological and pathological processes, such as morphogenesis, angiogenesis, tissue repair, and metastasis. Aberrant expression of MMPs occurs in several solid tumors, and is therefore considered to be related to the invasive potential of these tumors. Based on promising data from preclinical and early clinical evaluations, two MMP inhibitors (marimastat, prinostat) are now being tested in ongoing Phase III clinical trials. </p> <p>More potential targeting agents focusing on other cell receptors, such as fibroblasts growth factor receptor (FGFR), or other downstream components such as histone deacetylases (HDAC), are also currently under test. </p> </section> </section> </section> <section id="CD011461-sec-0028"> <h3 class="title" id="CD011461-sec-0028">Why it is important to do this review</h3> <p>The management of AGC has a very limited evolution in the last decade. Despite the development of new chemotherapy regimens and the introduction of novel adjuvant treatments, the prognosis for people with AGC has not substantially improved, with median overall survival remaining less than one year. Recently, trials provided some promising results regarding molecular‐targeted therapy, in particular those targeting HER‐2 receptors, raising the possibility that the development of these agents could be an approach which might produce better outcomes for people with AGC. However, many questions remain, such as: </p> <p> <ul id="CD011461-list-0001"> <li> <p>Are molecular‐targeted agents clinically beneficial for people with AGC?</p> </li> <li> <p>Which pathway or molecule is the most efficient target for drug development?</p> </li> <li> <p>Which is the most effective way to apply these drugs:</p> <ul id="CD011461-list-0002"> <li> <p>Should they be for all people with AGC or only for those with certain genetic biomarkers?</p> </li> <li> <p>Should they be used alone or together with other chemotherapy agent?</p> </li> </ul> </li> </ul> </p> <p>We therefore feel there is a need for a systematic review to evaluate the effectiveness and safety profile of molecular‐targeted therapy. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011461-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011461-sec-0029"></div> <p>To evaluate the efficacy and safety of molecular‐targeted therapy , either alone or in combination with chemotherapy, in people with advanced gastric cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011461-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011461-sec-0030"></div> <section id="CD011461-sec-0031"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011461-sec-0032"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs). We included studies reported as full text, those published as abstract only, and unpublished data. </p> </section> <section id="CD011461-sec-0033"> <h4 class="title">Types of participants</h4> <p>We included adults (aged 18 years and older) with histologically‐confirmed adenocarcinoma of the stomach or of the gastro‐esophageal junction with locally advanced unresectable (M0) or metastatic (M1) disease. We considered people with esophageal adenocarcinoma, if they had been enrolled in the trial together with those with gastric and gastro‐esophageal junction cancer, to be eligible, since this type of cancer also typically arises adjacent to the stomach (<a href="./references#CD011461-bbs2-0057" title="PohlH , WelchHG . The role of over diagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. Journal of the National Cancer Institute2005;97(2):142‐6. ">Pohl 2005</a>). We excluded people with the following characteristics: </p> <p> <ol id="CD011461-list-0003"> <li> <p>Previously treated by chemotherapy for metastatic or locally‐advanced unresectable cancer; </p> </li> <li> <p>With known brain metastasis;</p> </li> <li> <p>With other malignant disease in the previous five years, apart from basal‐cell cancer of the skin. </p> </li> </ol> </p> </section> <section id="CD011461-sec-0034"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing:</p> <p> <ul id="CD011461-list-0004"> <li> <p>Molecular‐targeted agents (e.g. anti‐EGFR agents, VEGF‐targeting agents) plus conventional chemotherapy versus conventional chemotherapy alone; </p> </li> <li> <p>Molecular‐targeted agents (e.g. anti‐EGFR agents, VEGF‐targeting agents) versus no treatment. </p> </li> </ul> </p> </section> <section id="CD011461-sec-0035"> <h4 class="title">Types of outcome measures</h4> <section id="CD011461-sec-0036"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011461-list-0005"> <li> <p>Overall survival (OS): survival until death from all causes;</p> </li> <li> <p>Progression‐free survival (PFS): time from randomization to either death or disease progression, whichever occurs first. Disease progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) (<a href="./references#CD011461-bbs2-0067" title="TherasseP , ArbuckSG , EisenhauerEA , WandersJ , KaplanRS , RubinsteinL , et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada, National Cancer Institute of the United States. Journal of the National Cancer Institute2000;92(3):205‐16. ">Therasse 2000</a>) as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter recorded since the treatment started or the appearance of one or more new lesions. </p> </li> </ol> </p> </section> <section id="CD011461-sec-0037"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011461-list-0006"> <li> <p>Overall response: assessed response according to RECIST guidelines (<a href="./references#CD011461-bbs2-0067" title="TherasseP , ArbuckSG , EisenhauerEA , WandersJ , KaplanRS , RubinsteinL , et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada, National Cancer Institute of the United States. Journal of the National Cancer Institute2000;92(3):205‐16. ">Therasse 2000</a>); </p> </li> <li> <p>Quality of life, measured by a validated scale (e.g. EORTC QOL30 global health status scale); </p> </li> <li> <p>Adverse events/side effects: such as anemia/neutropenia, nausea, diarrhea, and skin pigmentation, graded severity with the National Cancer Institute‐Common Terminology Criteria for Adverse Events (NCI‐CTCAE), including the percentage of treatment‐related deaths. </p> </li> </ol> </p> </section> </section> </section> <section id="CD011461-sec-0038"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011461-sec-0039"> <h4 class="title">Electronic searches</h4> <p>We conducted a literature search to identify all published and unpublished RCTs. The literature search identified potential studies in all languages. We translated the non‐English‐language papers and fully assessed them for potential inclusion in the review as necessary. </p> <p>We searched the following electronic databases to identify potential studies for inclusion:</p> <p> <ul id="CD011461-list-0007"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 12, 2015) (<a href="./appendices#CD011461-sec-0094">Appendix 2</a>); </p> </li> <li> <p>MEDLINE (1946 to 4th December 2015) (<a href="./appendices#CD011461-sec-0095">Appendix 3</a>); </p> </li> <li> <p>EMBASE (1980 to 4th December 2015) (<a href="./appendices#CD011461-sec-0096">Appendix 4</a>); </p> </li> <li> <p>CINAHL (1982 to 4th December 2015) (<a href="./appendices#CD011461-sec-0097">Appendix 5</a>). </p> </li> </ul> </p> <p>We also conducted a search of <a href="http://www.ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> for planned and ongoing trials. </p> </section> <section id="CD011461-sec-0040"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and reviewed articles for additional references. We contacted authors of identified trials and asked them to identify other published and unpublished studies. We also asked experts in the field and manufacturers of relevant drugs to provide details of current clinical trials and any relevant unpublished material. </p> <p>We handsearched the abstracts from 1995 to 2014 from the American Digestive Disease Week (DDW) published in <i>Gastroenterology,</i> the United European Gastroenterology Week (UEGW) published in <i>Gut</i>, and the proceedings of the American Society of Clinical Oncology (ASCO) and the European Cancer Congress (ESMO‐ECCO). </p> <p>We searched for errata or retractions from eligible trials on <a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a> on 4 December 2015. </p> </section> </section> <section id="CD011461-sec-0041"> <h3 class="title" id="CD011461-sec-0041">Data collection and analysis</h3> <section id="CD011461-sec-0042"> <h4 class="title">Selection of studies</h4> <p>Two review authors (HS, JZ) independently screened the titles and abstracts for potential inclusion of all the studies we identified as a result of the search. We coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We then retrieved the full‐text study reports/publications for further assessment. Similarly, two review authors (HS, JZ) independently screened the full text and identified studies for inclusion, and recorded the reasons for exclusion of the ineligible studies. We resolved any disagreement through discussion or, if required, by consulting a third review author (DL). Finally, we identified and excluded duplicates and collated multiple reports of the same study, so that each study rather than each report was the unit of interest in the review. We documented the selection process in sufficient detail to complete a PRISMA flow diagram and <a href="./references#CD011461-sec-0105" title="">Characteristics of included studies</a> and <a href="./references#CD011461-sec-0106" title="">Characteristics of excluded studies</a> tables. </p> </section> <section id="CD011461-sec-0043"> <h4 class="title">Data extraction and management</h4> <p>We used a standard data collection form for study characteristics and outcome data, which has been piloted on at least one study in the review. One review author (HS) extracted study characteristics from the included studies, which in detail were: </p> <p> <ol id="CD011461-list-0008"> <li> <p>Methods: study design, total duration study and run‐in, number of study centers and location, study setting, withdrawals, date of study </p> </li> <li> <p>Participants: number (N), mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, exclusion criteria </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, excluded medications</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, time points reported</p> </li> <li> <p>Notes: funding for trial, notable conflicts of interest of trial authors</p> </li> </ol> </p> <p>Two review authors (HS, JZ) independently extracted outcome data from the included studies. We noted in the <a href="./references#CD011461-sec-0105" title="">Characteristics of included studies</a> table whether outcome data were reported in an unusable way. We resolved disagreements by consensus or by involving a third review author (DL). One review author (HS) copied across the data from the data collection form into the Review Manager 5 file. Then we double‐checked that the data were entered correctly by comparing the study reports with how the data were presented in the systematic review. A second review author spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD011461-sec-0044"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (HS, JZ) independently assessed the risks of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011461-bbs2-0044" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved any disagreement by discussion or by involving a third assessor (DL). We assessed the risk of bias according to the following domains: </p> <p> <ol id="CD011461-list-0009"> <li> <p>Random sequence generation;</p> </li> <li> <p>Allocation concealment;</p> </li> <li> <p>Blinding of participants and personnel (for all outcomes);</p> </li> <li> <p>Blinding of outcome assessment (overall survival, serious adverse events);</p> </li> <li> <p>Blinding of outcome assessment (progression‐free survival; response, adverse events, quality of life); </p> </li> <li> <p>Incomplete outcome data (for all outcomes);</p> </li> <li> <p>Selective outcome reporting;</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low or unclear, and provide a quote from the study report together with a justification for our judgment in the 'Risk of bias' table. We then summarized the 'Risk of bias' judgments across different studies for each of the domains listed. We considered blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for all‐cause mortality may be very different from that for a participant‐reported pain scale). Where information on risk of bias relates to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contribute to that outcome. </p> <section id="CD011461-sec-0045"> <h5 class="title">Assesment of bias in conducting the systematic review</h5> <p>We conducted the review according to our previously published protocol, and reported any deviations from it in the <a href="#CD011461-sec-0103">Differences between protocol and review</a> section of the full review. </p> </section> </section> <section id="CD011461-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>We analyzed dichotomous data as odds ratios (ORs) with 95% confidence intervals (CIs), and continuous data as mean differences (MDs) or standardized mean differences (SMDs) with 95% CIs. We ensured that higher scores for continuous outcomes have the same meaning for the particular outcome, explaining the direction and reporting where the directions were reversed if this was necessary. For time‐to‐event data, we used methods of survival analysis and expressed the intervention effect as a hazard ratio (HR). In all analyses, we calculated the 95% confidence interval (CI). We extracted the HR for each individual trial directly from published data, if available, or alternatively using reported summary statistics or Kaplan‐Meier curves, as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011461-bbs2-0044" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>; <a href="./references#CD011461-bbs2-0056" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>; <a href="./references#CD011461-bbs2-0068" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8(16):1‐16. ">Tierney 2007</a>). </p> <p>We undertook meta‐analyses only where this was meaningful, i.e. if the treatments, participants and the underlying clinical question were similar enough for pooling to make sense. </p> <p>A common way that trialists indicate when they have skewed data is by reporting medians and interquartile ranges. When we encountered this we noted that the data were skewed and considered the implications of this. </p> <p>Where multiple trial arms were reported in a single trial, we included only the relevant arms. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) were entered into the same meta‐analysis, we halved the control group to avoid double‐counting. </p> </section> <section id="CD011461-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>We only considered RCTs. We did not find any probable RCTs with non‐standard designs. But if we identify such trials in future updates, we will assess non‐standard designs, such as cluster‐randomized trials, in order to avoid unit‐of‐analysis errors, including: </p> <p> <ol id="CD011461-list-0010"> <li> <p>Recruitment bias;</p> </li> <li> <p>Baseline imbalance;</p> </li> <li> <p>Loss of clusters;</p> </li> <li> <p>Incorrect analysis;</p> </li> <li> <p>Comparability with individually‐randomized trials.</p> </li> </ol> </p> </section> <section id="CD011461-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors in order to verify key study characteristics or to obtain missing numerical outcome data where possible (e.g. when a study was presented as an abstract only). If we could not elicit a reply from the study authors after repeated attempts, we dropped these incomplete data from the analysis, stating this clearly in the Results section and discussing it further under the <a href="#CD011461-sec-0085">Potential biases in the review process</a> section of the <a href="#CD011461-sec-0081">Discussion</a>. </p> </section> <section id="CD011461-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>We conducted tests for heterogeneity using the Chi² test, with significance set at P &lt; 0.1. We used the I² statistic (<a href="./references#CD011461-bbs2-0043" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>) to estimate the total variation across studies due to heterogeneity; we consider I² less than 25% as low‐level, 25% to 50% as moderate‐level, and greater than 50% as high‐level heterogeneity. If we found high levels of heterogeneity (I² &gt; 50%, <a href="./references#CD011461-bbs2-0044" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) for the primary outcomes, we explored its possible sources using the sensitivity and subgroup analyses described below. </p> </section> <section id="CD011461-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to contact study authors to ask them to provide missing outcome data. Where this was not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results by a sensitivity analysis<b>.</b> </p> <p>We created funnel plot to explore possible publication biases when we were able to pool 10 or more trials. </p> </section> <section id="CD011461-sec-0051"> <h4 class="title">Data synthesis</h4> <p>We used Review Manager 5 (<a href="./references#CD011461-bbs2-0060" title="The Nordic Cochrane Centre: The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2013. ">Review Manager 2014</a>) for pooling data and statistical analysis.For time‐to‐event outcomes (OS, PFS), we combined data using the generic inverse variance (GIV) method, and we presented measurements of treatment effects as HRs and 95% CIs. Since the design of the agents of interest is based on a different mechanism (targeting different pathways), we used a random‐effects model for primary analyses. For subgroup analysis, if we found the studies to be homogeneous in terms of age, diagnostic subtype, intervention type, and intervention duration, we used both the fixed‐effect model and the random‐effects model. We then compared the results from the two different models. In the absence of heterogeneity and significant reporting bias, these two models should yield the same results. In this case, we reported the results from the fixed‐effect model only. Otherwise, if the results were different, indicating significant heterogeneity, we reported the results from the random‐effects model only. </p> <section id="CD011461-sec-0052"> <h5 class="title">'Summary of findings' table</h5> <p>We created a 'Summary of findings' table using the GRADEpro software (<a href="./references#CD011461-bbs2-0040" title="BrozekJ , OxmanA , SchünemannH . GRADEprofiler (GRADEpro). Version 3.2. GRADE Working Group, 2008. ">GRADEprofiler 2008</a>). We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it related to the studies which contribute data to the meta‐analyses for the prespecified outcomes. We used methods and recommendations described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011461-bbs2-0044" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We then justified all decisions to down‐ or upgrade the quality of studies using footnotes, and made comments to aid the reader's understanding of the review where necessary. We considered whether there was any additional outcome information that we could not incorporate into meta‐analyses; and if so we noted it in the comments, stating whether it supported or contradicted the information from the meta‐analyses. </p> </section> </section> <section id="CD011461-sec-0053"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses:</p> <p> <ol id="CD011461-list-0011"> <li> <p>Participants receiving molecular‐targeted agents for different purposes: adjunctive therapy or monotherapy (molecular‐targeted agents plus conventional chemotherapy versus conventional chemotherapy alone; molecular‐targeted agents versus placebo); </p> </li> <li> <p>Different types of molecular‐targeted agents: e.g. anti‐EGFR agents, VEGF‐targeting agents; </p> </li> <li> <p>Participants with and without specifically molecular prognostic markers, such as V‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (K‐Ras) mutation, EGFR gene copy number, and HER‐2 status. </p> </li> </ol> </p> <p>We used the following outcomes in subgroup analyses:</p> <p> <ol id="CD011461-list-0012"> <li> <p>Overall survival (OS);</p> </li> <li> <p>Progression‐free survival (PFS).</p> </li> </ol> </p> <p>We firstly examined the differences between subgroups by visual inspections of their confidence intervals; non‐overlapping confidence intervals indicate a statistically significant difference in treatment effect between subgroups. We then used the approach of <a href="./references#CD011461-bbs2-0032" title="BorensteinM , HedgesLV , HigginsJPT , RothsteinHR . Introduction to Meta‐Anaysis (Statistics in Practice). Chichester (UK): John Wiley &amp; Sons, 2008. ">Borenstein 2008</a> to formally investigate differences between two or more subgroups. To ensure the statistical power, we only conducted subgroup tests for those outcomes with three or more trials contributing data. </p> </section> <section id="CD011461-sec-0054"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses defined a priori to assess the robustness of our conclusions. We did this by repeating the analyses in order to explore the influence of the following factors on effect size: </p> <p> <ol id="CD011461-list-0013"> <li> <p>Exclusion of unpublished studies;</p> </li> <li> <p>Exclusion of lower‐quality studies (those at high or unclear risk of bias relating to randomization, blinding or attrition); </p> </li> <li> <p>Use of a fixed‐effect model (provided that a random‐effects model was initially used).</p> </li> </ol> </p> <section id="CD011461-sec-0055"> <h5 class="title">Reaching conclusions</h5> <p>We based our conclusions only on findings from the quantitative or narrative synthesis of included studies for this review. We avoided making recommendations for practice and our implications for research give the reader a clear sense of where the focus of any future research in the area should be and what the remaining uncertainties are. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011461-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011461-sec-0056"></div> <section id="CD011461-sec-0057"> <h3 class="title">Description of studies</h3> <p>We have summarized the characteristics of the studies in the <a href="./references#CD011461-sec-0105" title="">Characteristics of included studies</a> tables. </p> <section id="CD011461-sec-0058"> <h4 class="title">Results of the search</h4> <p>The electronic search in December 2015 identified 2791 citations (114 from CENTRAL, 1463 from MEDLINE, 1214 from EMBASE). Handsearching found no relevant abstracts from conference proceedings. Of these 2791 records, we considered 126 (accounting for 78 reports after excluding duplicates) to be highly relevant after checking their abstracts, and we therefore tried to obtain the full texts for detailed assessment. Finally, 45 reports describing 20 different studies met our inclusion criteria. However, ten trials were available only as abstracts, among which seven were ongoing studies (<a href="./references#CD011461-bbs2-0025" title="Pazopanib with 5‐Fluorouracil, leucovorin and oxaliplatin (FLO) as 1st‐line treatment in advanced gastric cancer; a randomized hase‐II‐study of the Arbeitsgemeinschaft Internistische Onkologie. Ongoing studyNovember 2011. ">NCT01503372</a>; <a href="./references#CD011461-bbs2-0026" title="A study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2‐negative and Met‐positive gastroesophageal cancer (MetGastric). Ongoing studyNovember 2012. ">NCT01662869</a>; <a href="./references#CD011461-bbs2-0028" title="A randomized, double‐blind, placebo‐controlled Phase 3 study of capecitabine and cisplatin with or without ramucirumab as first‐line therapy in patients with metastatic gastric or gastroesophageal junction adenocarcinoma (RAINFALL). Ongoing studyJanuary 2015. ">NCT02314117</a>; <a href="./references#CD011461-bbs2-0024" title="MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX alone or in combination with AMG 102 or panitumumab as first‐line treatment in patients with advanced gastroesophageal adenocarcinoma. Ongoing studyJanuary 2011. ">NCT01443065</a>; <a href="./references#CD011461-bbs2-0023" title="Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction, metastatic or not amenable to curative surgery according to HER2 and EGFR status: a randomized Phase II trial. Ongoing study May 13 2010. ">NCT01123473</a>; <a href="./references#CD011461-bbs2-0027" title="A study of perjeta (Pertuzumab) in combination with herceptin (trastuzumab) and chemotherapy in patients with HER2‐positive metastatic gastroesophageal junction or gastric cancer. Ongoing studyJune 2013. ">NCT01774786</a>; <a href="./references#CD011461-bbs2-0022" title="A randomised phase II study evaluating weekly docetaxel, cisplatin, fluoropyrimidine (wTCF) plus or minus panitumumab in advanced oesophago‐gastric cancer. Ongoing studyMarch 2010. ">ACTRN12609000109202</a>) with no data reported (<a href="./references#CD011461-bbs2-0022" title="A randomised phase II study evaluating weekly docetaxel, cisplatin, fluoropyrimidine (wTCF) plus or minus panitumumab in advanced oesophago‐gastric cancer. Ongoing studyMarch 2010. ">ACTRN12609000109202</a> suspended enrolment because of an unplanned and unfavorable safety review). The other three were completed trials (<a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0020" title="WahabMA , EzzelarabL , ElBendaryS . Cetuximab plus capecitabine and oxaloplatin for chemonaive patients with advanced gastric cancer. Annals of Oncology2011;22:v50. ">Wahab 2011</a>; <a href="./references#CD011461-bbs2-0021" title="WangJW , ChiY , ZhengZX , QuT , ZhouAP , YangL , et al. Randomized, single‐centered, phase II clinical trial of nimotuzumab plus cisplatin and S‐1 as first‐line therapy in patients with advanced gastric cancer. Journal of Clinical Oncology2012;30(Suppl; abstr):e14668. ">Wang 2012</a>). We were unable to access the full data and relevant study information for <a href="./references#CD011461-bbs2-0020" title="WahabMA , EzzelarabL , ElBendaryS . Cetuximab plus capecitabine and oxaloplatin for chemonaive patients with advanced gastric cancer. Annals of Oncology2011;22:v50. ">Wahab 2011</a> and <a href="./references#CD011461-bbs2-0021" title="WangJW , ChiY , ZhengZX , QuT , ZhouAP , YangL , et al. Randomized, single‐centered, phase II clinical trial of nimotuzumab plus cisplatin and S‐1 as first‐line therapy in patients with advanced gastric cancer. Journal of Clinical Oncology2012;30(Suppl; abstr):e14668. ">Wang 2012</a>, having received no response to our attempts to contact the authors. We therefore list these two trials as <a href="./references#CD011461-bbs1-0003" title="">Studies awaiting classification</a>. For <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>, we found details about the trial by referring to a presentation at ASCO available on the Internet. </p> <p>We didn't find any errata or retractions from eligible trials. <a href="#CD011461-fig-0002">Figure 2</a> shows the details of the search results. </p> <div class="figure" id="CD011461-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study Flow diagram for RCTs" data-id="CD011461-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study Flow diagram for RCTs</p> </div> </div> </div> </section> <section id="CD011461-sec-0059"> <h4 class="title">Included studies</h4> <p>After evaluation of eligible articles, we include 11 trials, corresponding to 11 individual RCTs (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0005" title="KoizumiW , YamaguchiK , HosakaH , TakinishiY , NakayamaN , HaraT , et al. Randomised phase II study of S‐1/cisplatin plus TSU‐68 vs S‐1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer2013;109(8):2079‐86. ">Koizumi 2013</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>; <a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>; <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>) with 4085 participants. The <a href="./references#CD011461-sec-0105" title="">Characteristics of included studies</a> tables summarize the details of the included studies. Agents under investigations targeted the EGFR (trastuzumab/lapatinib /cetuximab /matuzumab/panitumumab) or the VEGF (TSU‐68/bevacizumab) pathway. </p> <section id="CD011461-sec-0060"> <h5 class="title">Study design</h5> <p>Six studies had an open‐label design without application of placebo (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0005" title="KoizumiW , YamaguchiK , HosakaH , TakinishiY , NakayamaN , HaraT , et al. Randomised phase II study of S‐1/cisplatin plus TSU‐68 vs S‐1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer2013;109(8):2079‐86. ">Koizumi 2013</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>; <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>; <a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>; <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>), while the other five RCTs used a double‐blinded and parallel‐group design. With the exception of <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>, all the included trials were multicenter, with seven international trials, and the other three located in Japan (<a href="./references#CD011461-bbs2-0005" title="KoizumiW , YamaguchiK , HosakaH , TakinishiY , NakayamaN , HaraT , et al. Randomised phase II study of S‐1/cisplatin plus TSU‐68 vs S‐1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer2013;109(8):2079‐86. ">Koizumi 2013</a>), China (<a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>), and the UK (<a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>). </p> </section> <section id="CD011461-sec-0061"> <h5 class="title">Participants</h5> <p>All included trials enrolled participants with histologically‐confirmed advance gastric adenocarcinoma. Most of them allowed the inclusion of adenocarcinomas of gastro‐esophageal junction (except for <a href="./references#CD011461-bbs2-0005" title="KoizumiW , YamaguchiK , HosakaH , TakinishiY , NakayamaN , HaraT , et al. Randomised phase II study of S‐1/cisplatin plus TSU‐68 vs S‐1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer2013;109(8):2079‐86. ">Koizumi 2013</a> and <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>); and three of them also involved adenocarcinomas originating from the esophagus (<a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>) or the distal esophagus (<a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>). Three studies applied a specific biomarker for participant selection: HER2‐positive was required for participant enrolment in <a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a> and <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; and all participants were EGFR‐positive in <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>. </p> </section> <section id="CD011461-sec-0062"> <h5 class="title">Interventions</h5> <p>All included RCTs compared molecular‐targeted agents plus conventional chemotherapy versus conventional chemotherapy alone. No trial applied a molecular‐targeted agent for monotherapy. Six trials assessed the addition of EGFR‐targeting agents: trastuzumab (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>)/lapatinib (<a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>)/cetuximab (<a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>; <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>)/matuzumab (<a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>)/panitumumab (<a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>) to standard chemotherapy. Three trials focused on VEGF‐targeting agents: TSU‐68 (<a href="./references#CD011461-bbs2-0005" title="KoizumiW , YamaguchiK , HosakaH , TakinishiY , NakayamaN , HaraT , et al. Randomised phase II study of S‐1/cisplatin plus TSU‐68 vs S‐1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer2013;109(8):2079‐86. ">Koizumi 2013</a>)/bevacizumab (<a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>). The other two trials used experimental drugs targeting the Tie2 receptor and its ligands (angiopoientin‐1 and ‐2) (<a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>), another pathway for tumor angiogenesis, and the HGF/MET pathway (<a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>), respectively. </p> <p><a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a> and <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a> compared two different doses of molecular‐targeted agents plus chemotherapy versus chemotherapy alone, while the other RCTs had only one experimental group and one control group. </p> </section> <section id="CD011461-sec-0063"> <h5 class="title">Outcome measures</h5> <p>PFS was reported in all included RCTs. Apart from <a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>, the other primary outcome of our review, OS, was reported in 10 of the 11 included RCTs. </p> <p>For secondary outcomes, all the studies reported the overall response rate. However, since six RCTs (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>) allowed the enrolment of participants with non‐measurable disease, so that this outcome could not be recorded for these people, it was measured in only 3723 participants. Similarly, all studies documented adverse events. However, in three RCTs (<a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>; <a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>), only severe adverse events, classified as severity ≥ grade 3, were reported, with no data for non‐serious adverse events. In addition, three reports (<a href="./references#CD011461-bbs2-0005" title="KoizumiW , YamaguchiK , HosakaH , TakinishiY , NakayamaN , HaraT , et al. Randomised phase II study of S‐1/cisplatin plus TSU‐68 vs S‐1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer2013;109(8):2079‐86. ">Koizumi 2013</a>; <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>; <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>) only gave data for each adverse symptom or disease, with no overall percentage of adverse events or overall percentage of any severe adverse events. Quality of life was measured in only one included RCT (<a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>). </p> <p>Due to the inconsistencies of follow‐up duration between different trials (see <a href="#CD011461-sec-0059">Included studies</a>), these point estimated results need to be interpreted with caution. </p> </section> </section> <section id="CD011461-sec-0064"> <h4 class="title">Excluded studies</h4> <p>Please see <a href="./references#CD011461-sec-0106" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD011461-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD011461-fig-0003">Figure 3</a> summarizes the risk of bias in the included studies. Overall, five trials were well‐designed and well‐conducted, and therefore assessed as being at low risk of bias (<a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>), although for three of them (<a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>), the influence of the sponsor was apparent during the data analysis/interpretation and manuscript preparation stages. The other six trials were at high risk of bias (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0005" title="KoizumiW , YamaguchiK , HosakaH , TakinishiY , NakayamaN , HaraT , et al. Randomised phase II study of S‐1/cisplatin plus TSU‐68 vs S‐1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer2013;109(8):2079‐86. ">Koizumi 2013</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>; <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>; <a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>; <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>), mainly because there was no placebo comparator (open‐label design). For <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>, little information was available from the published paper for the risk of bias assessment; despite contacting the study authors we were unable to acquire more details. </p> <div class="figure" id="CD011461-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011461-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011461-sec-0066"> <h4 class="title">Allocation</h4> <p>One included trial (<a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>) did not explicitly state the exact method for 'randomisation'. We therefore considered it to be at unclear risk of selection bias. The other studies all described clearly how the random sequence was generated. For allocation concealment, we considered nine trials to be at low risk: eight allocated participants using a central interactive voice recognition system (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>), and one study involved central allocation via fax (<a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>). Two studies (<a href="./references#CD011461-bbs2-0005" title="KoizumiW , YamaguchiK , HosakaH , TakinishiY , NakayamaN , HaraT , et al. Randomised phase II study of S‐1/cisplatin plus TSU‐68 vs S‐1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer2013;109(8):2079‐86. ">Koizumi 2013</a>; <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>) had unclear risk, since they provided no information. </p> </section> <section id="CD011461-sec-0067"> <h4 class="title">Blinding</h4> <p>We considered five trials with a double‐blind, placebo‐controlled design (<a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a> ) to be at low risk of bias for blinding of participants and researchers, as well as blinding of outcome assessors. Six open‐label trials (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0005" title="KoizumiW , YamaguchiK , HosakaH , TakinishiY , NakayamaN , HaraT , et al. Randomised phase II study of S‐1/cisplatin plus TSU‐68 vs S‐1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer2013;109(8):2079‐86. ">Koizumi 2013</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>; <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>; <a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>; <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>) had no placebo comparator. We judged these studies to have a high risk of performance bias (e.g. through stress‐related mechanisms). </p> <p>For assessing detection bias, we classified the following outcomes as subjectively ascertained: PFS, quality of life, response and any adverse event. These outcomes could be affected by the outcome assessors' knowledge of treatment received. We considered OS and severe adverse events to be unlikely to be affected by blinding of outcome assessment. We assessed all trials to be at low risk of detection bias for objective outcomes. Besides these five investigator‐masked double‐blind studies, four open‐label RCTs also applied masked review for outcome evaluations to reduce the risk of detection bias (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0005" title="KoizumiW , YamaguchiK , HosakaH , TakinishiY , NakayamaN , HaraT , et al. Randomised phase II study of S‐1/cisplatin plus TSU‐68 vs S‐1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer2013;109(8):2079‐86. ">Koizumi 2013</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>; <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>). We therefore considered these trials to have low risk of detection bias for measuring subjective outcomes. We judged <a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a> as 'unclear bias', since although it had no masking for assessors, a central monitoring system was applied to control the quality of outcome measurements. We classified one other study as being at unclear risk of bias, since no relevant information was provided for assessment (<a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>). </p> </section> <section id="CD011461-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>We considered all the included studies to be at low risk of bias, either because the number of participants missing from follow‐up was very low (dropout rates below 5%) (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0005" title="KoizumiW , YamaguchiK , HosakaH , TakinishiY , NakayamaN , HaraT , et al. Randomised phase II study of S‐1/cisplatin plus TSU‐68 vs S‐1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer2013;109(8):2079‐86. ">Koizumi 2013</a>; <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>), or the efficacy analysis (analysis for survival time) was done on the intention‐to‐treat population of all participants randomly allocated to treatment (<a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>; <a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>). All the studies reported overall response rate, but only among participants with measurable disease. </p> </section> <section id="CD011461-sec-0069"> <h4 class="title">Selective reporting</h4> <p>We judged all of the included studies to be at low risk of selective outcome reporting. Seven studies (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>; <a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>) had well‐documented study protocols which were consistent with their published full reports. We also classified the other four studies as being at low selective reporting risk (<a href="./references#CD011461-bbs2-0005" title="KoizumiW , YamaguchiK , HosakaH , TakinishiY , NakayamaN , HaraT , et al. Randomised phase II study of S‐1/cisplatin plus TSU‐68 vs S‐1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer2013;109(8):2079‐86. ">Koizumi 2013</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>; <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>; <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>), since they reported all important outcomes (i.e. OS, PFS, overall response, severe adverse events), although no study protocol was available. However, we found very limited information for quality of life, since only one trial (<a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>) evaluated it. All studies included data on severe adverse events. However, summary data were available for only eight of them (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>; <a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>). Similarly, we extracted summary data on general adverse events from only five studies (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>). </p> </section> <section id="CD011461-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a> was identified to be with unclear risk of other potential bias due to its early termination. We considered all other trials to be at low risk of other potential biases. However, all the trials except for <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a> stated clearly that they were supported by pharmaceutical companies, and the role of the sponsors in some funded studies was critical: in six trials (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>), the sponsors were involved in study design, data collection, management and statistical analysis. The other five RCTs confirmed the independence of the conduct and data collection of the study. </p> </section> </section> <section id="CD011461-sec-0071"> <h3 class="title" id="CD011461-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD011461-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings: Molecular‐targeted therapy plus chemotherapy compared to chemotherapy alone for people with advanced gastric cancer</a> </p> <p>We extracted summary data from all 11 included studies. For the trials with multiple intervention groups with different doses of experimental agent but one control group, we summed the number of participants for the primary analysis, irrespective of the dose level they received, to detect the global effect of molecular‐targeted therapy. </p> <section id="CD011461-sec-0072"> <h4 class="title">Primary outcomes</h4> <section id="CD011461-sec-0073"> <h5 class="title">Effect of molecular‐targeted therapy plus chemotherapy, compared with chemotherapy alone, with or without placebo, on overall survival </h5> <p>With the exception of <a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>, which was a small Phase II trial, all studies, involving 3843 participants, reported an evaluation of overall survival. There was statistically significant heterogeneity between the results of individual trials (I² = 61%, P = 0.005). Therefore, as planned, we used a random‐effects model for pooling the results. The effect of molecular therapy on survival was uncertain due to wide confidence intervals and inconsistency of effect across the studies. The pooled HR was 0.92 (95% CI 0.80 to 1.05) (<a href="./references#CD011461-fig-0007" title="">Analysis 1.1</a>; <a href="#CD011461-fig-0004">Figure 4</a>). The quality of the evidence was low, due to performance bias and inconsistency between the results of the included studies (<a href="./full#CD011461-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD011461-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: main analyses, outcome: 1.1 Overall survival." data-id="CD011461-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: main analyses, outcome: 1.1 Overall survival. </p> </div> </div> </div> <p>We performed several sensitivity analyses when pooling data from these trials. When we performed a complete‐case analysis but applied a fixed‐effect model, the confidence interval for the main HR (0.92) became narrower (0.85 to 0.99), indicating a statistically significant benefit. In addition, when we restricted the analysis to trials at low risk of bias (<a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>), we found there was no statistically significant between‐trial heterogeneity (I² = 0%, P = 0.42), and the HR was 0.90 (95% CI 0.79 to 1.01). </p> </section> <section id="CD011461-sec-0074"> <h5 class="title">Effect of molecular‐targeted therapy plus chemotherapy, compared with chemotherapy alone with or without placebo, on progression‐free survival </h5> <p>All trials provided data regarding progression‐free survival (4014 participants). As with results for overall survival, we found no evidence of significant benefit of additional molecular‐targeted therapy in prolonging progression‐free survival; the main analysis including results from all studies demonstrated a HR of 0.90 (95% CI 0.78 to 1.04) (<a href="./references#CD011461-fig-0008" title="">Analysis 1.2</a>; <a href="#CD011461-fig-0005">Figure 5</a>). Also, we detected high heterogeneity between individual trial results (I² = 64%, P = 0.002). The quality of evidence was low due to performance bias and inconsistency between the results of included studies (<a href="./full#CD011461-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD011461-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: main analyses, outcome: 1.2 Progression‐free survival." data-id="CD011461-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: main analyses, outcome: 1.2 Progression‐free survival. </p> </div> </div> </div> <p>However, results produced by a fixed‐effect model showed a small but significant benefit (HR 0.90, 95% CI 0.83 to 0.97). Restricting the analysis to trials at low risk of bias only (<a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>) indicated a statistically significant benefit of molecular‐targeted treatment (HR 0.82, 95% CI 0.74 to 0.92), without evidence of statistical heterogeneity (I² = 0%, P = 0.51). </p> </section> <section id="CD011461-sec-0075"> <h5 class="title">Effect of molecular‐targeted therapy plus chemotherapy, compared with chemotherapy alone, with or without placebo, on overall response </h5> <p>All trials provided data regarding overall response. However, since six RCTs (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>) allowed the recruitment of participants with non‐measurable disease, this outcome was restricted to the 3723 participants who had measurable tumors. Overall, 816 (42.1%) of 1936 participants assigned to the molecular‐targeted therapy plus conventional chemotherapy group were subsequently assessed as having either a complete or a partial response, compared with 653 (36.5%) of 1787 participants allocated to the chemotherapy‐only control treatment. There was statistically significant heterogeneity between individual trial results (I² = 52%, P = 0.02). Using a random‐effects model , we observed a statistically significant increase in tumor response rate among participants assigned to the adjuvant molecular‐targeted therapy group (OR 1.24, 95% CI 1.00 to 1.55) (<a href="./references#CD011461-fig-0009" title="">Analysis 1.3</a>; <a href="#CD011461-fig-0006">Figure 6</a>). The quality of evidence was low due to performance bias and inconsistency between results of included studies (<a href="./full#CD011461-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD011461-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: main analyses, outcome: 1.3 Overall response rate." data-id="CD011461-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: main analyses, outcome: 1.3 Overall response rate. </p> </div> </div> </div> <p>When we switched to a fixed‐effect model, the OR was 1.28 (95% CI 1.12 to 1.46). Sensitivity analysis with trials at low risk of bias produced similar but more pronounced results (OR 1.41, 95% CI 1.15 to 1.73). Importantly, the duration of follow‐up varied considerably between different studies; the median follow‐up time ranged from 5.3 months (<a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>) to 28.5 months (<a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>). It should be noted that this disparity would also influence the observed tumor response rate. </p> </section> <section id="CD011461-sec-0076"> <h5 class="title">Effect of molecular‐targeted therapy plus chemotherapy, compared with chemotherapy alone, with or without placebo, on quality of life </h5> <p>Only one trial (<a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>) reported these data. The absolute number of participants with follow‐up data in the different trial arms was very small, with 21 participants from the experimental groups and 32 from the control group completing the evaluation, using the EORTC QOL30 global health status scale. The chemotherapy‐alone group achieved higher mean scores than the experimental group, both at baseline and at the end of treatment. The score changes indicated there was no relevant difference between these two arms overall, but we downgraded the evidence to very low since the study was at a high risk of bias from the low number of participants and the wide confidence interval around the mean effect (<a href="./references#CD011461-fig-0010" title="">Analysis 1.4</a>; <a href="./full#CD011461-tbl-0001">summary of findings Table for the main comparison</a>). The quality of evidence was very low, due to notable performance/detection bias, and imprecision (<a href="./full#CD011461-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD011461-sec-0077"> <h5 class="title">Effect of molecular‐targeted therapy plus chemotherapy, compared with chemotherapy alone, with or without placebo, on adverse events </h5> <p>Five studies (2290 participants) provided data on the proportion of participants with any adverse event (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>). Overall, there were 1185 (98.3%) out of 1205 participants randomized to the experimental groups who experienced adverse events, compared with 1044 (96.2%) of 1085 participants in the control groups. There was no statistically significant heterogeneity between individual trial results (I² = 0%, P = 0.60). We found evidence (using a random‐effects model) of an increased risk of experiencing any adverse event among participants with molecular‐targeted combination treatment (OR 2.23, 95% CI 1.27 to 3.92) (<a href="./references#CD011461-fig-0011" title="">Analysis 1.5</a>), compared to those with chemotherapy only. Similarly, there was a significant excess risk of serious adverse events with molecular‐targeted therapy, based on data from eight studies (3800 participants): OR 1.19 (95% CI 1.03 to 1.37; I² = 0%) (<a href="./references#CD011461-fig-0012" title="">Analysis 1.6</a>) (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>; <a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>). </p> <p>As well as performance/detection bias, we considered there to be a risk of possible selective reporting bias, as three studies only provided data for severe adverse events, and another three had no summary data for pooling, prompting us to downgrade the quality of evidence to low (<a href="./full#CD011461-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> <section id="CD011461-sec-0078"> <h4 class="title">Subgroup analysis</h4> <section id="CD011461-sec-0079"> <h5 class="title">Effect of molecular‐targeted therapy plus chemotherapy, compared with chemotherapy alone, with or without placebo, on overall survival and progression‐free survival, according to the type of molecular‐targeted agents </h5> <p>By pooling results from three RCTs (<a href="./references#CD011461-bbs2-0005" title="KoizumiW , YamaguchiK , HosakaH , TakinishiY , NakayamaN , HaraT , et al. Randomised phase II study of S‐1/cisplatin plus TSU‐68 vs S‐1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer2013;109(8):2079‐86. ">Koizumi 2013</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>), with 1067 participants, we found no evidence that the application of VEGF‐targeting agents could benefit people with AGC, with respect both to overall survival time (HR 0.90, 95% CI 0.76 to 1.06) (<a href="./references#CD011461-fig-0013" title="">Analysis 2.1</a>) and to progression‐free survival (HR 0.87, 95% CI 0.71 to 1.05) (<a href="./references#CD011461-fig-0014" title="">Analysis 2.2</a>). Similarly, we found no survival effect for EGFR‐targeting agents (2655 participants: <a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>; <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>; <a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>; <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>): for overall survival, the HR is 0.94 (95% CI 0.77 to 1.16) (<a href="./references#CD011461-fig-0013" title="">Analysis 2.1</a>), and for progression‐free survival, the HR is 0.93 (95% CI 0.76 to 1.14) (<a href="./references#CD011461-fig-0014" title="">Analysis 2.2</a>). Due to the presence of high‐level heterogeneity (74% and 75% respectively), we used a random‐effects model for these analyses. </p> <p>Tests for subgroup differences for both overall survival and progression‐free survival did not reach statistical significance (test for subgroup differences for overall survival: P = 0.72; I² = 0%, and for progression‐free survival: P = 0.62; I² = 0%). </p> </section> <section id="CD011461-sec-0080"> <h5 class="title">Effect of molecular‐targeted therapy plus chemotherapy, compared with chemotherapy alone, with or without placebo, on overall survival and progression‐free survival, according to specific molecular prognostic biomarker for participant selection </h5> <p>Three trials used biomarkers for participant selection: <a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a> and <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a> recruited participants only if their tumors demonstrated over‐expression of HER2 protein; and <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a> required an EGFR‐positive tumor when recruiting participants. On the basis of the current data, we found a possible benefit when applying molecular‐targeted agents to participants with HER2‐positive tumors (HR 0.80, 95% CI 0.63 to 1.02 for overall survival (2 trials), and HR 0.78, 95% CI 0.63 to 0.95 for progression‐free survival (2 trials)) ( <a href="./references#CD011461-fig-0015" title="">Analysis 3.1</a>; <a href="./references#CD011461-fig-0016" title="">Analysis 3.2</a>). Among participants without tumor biomarker selection, and with an EGFR‐positive tumor, the possibility of benefiting from adjuvant molecular‐targeted therapy was low (<a href="./references#CD011461-fig-0015" title="">Analysis 3.1</a>; <a href="./references#CD011461-fig-0016" title="">Analysis 3.2</a>). </p> <p>We didn't perform tests for the subgroup differences owing to the limited number of trials involved in the each molecular prognostic biomarker subgroup. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011461-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011461-sec-0081"></div> <section id="CD011461-sec-0082"> <h3 class="title" id="CD011461-sec-0082">Summary of main results</h3> <p>This systematic review and meta‐analysis suggests that there is no clear evidence to support a survival benefit of molecular‐targeted therapy as a first‐line treatment for advance gastric cancer. However, since sensitivity analyses based on a fixed‐effect model and on study quality showed that the addition of molecular‐targeted therapy was significantly associated with improved overall and progression‐free survival, we conclude that the uncertainty of our findings is due to the low quality of the current evidence (inconsistency). In addition, subgroup analyses did not provide evidence that survival outcomes differed by the type of molecular‐targeted agent (EGFR‐ or VEGF‐targeting agents). Although one of the subgroups indicated a possible benefit for participants with HER2‐positive tumors on progression‐free survival, the test for interaction was not significant and this did not translate across to any improvement in survival. It is important to note that there were high levels of statistical heterogeneity within subgroups. This possibly reduced the power to detect significant differences in most of the subgroup analyses that we conducted. </p> <p>Furthermore, people with AGC with adjuvant molecular‐targeted treatment had an improved overall response rate compared to those receiving chemotherapy only (42.1% versus 36.5%, OR 1.24, 95% CI 1.00 to 1.55, P = 0.05). Also, based on incompletely‐extracted data, this additional treatment was significantly associated with an excess risk of experiencing adverse events (OR 2.23, 95% CI 1.27 to 3.92 for any adverse event; OR 1.19, 95% CI 1.03 to 1.37 for severe adverse events). </p> </section> <section id="CD011461-sec-0083"> <h3 class="title" id="CD011461-sec-0083">Overall completeness and applicability of evidence</h3> <p>To minimize the possible effect of publication bias, we conducted an exhaustive search involving unpublished or ongoing trials, and without any limitation on language. Except for one study without enough information to assess methodological issues (<a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>), the methodological quality of the remaining identified studies can in general be considered as adequate. However, we downgraded the quality of evidence due to wide confidence intervals and inconsistency of effect across the studies. </p> <p>Data regarding the efficacy of molecular‐targeted therapy for AGC are insufficient, and the included studies only partially addressed the objectives of our review. Firstly, we could not determine the effects of molecular‐targeted therapy on quality of life, since only one small trial provided data for this outcome. Secondly, all included RCTs compared molecular‐targeted agents plus conventional chemotherapy with conventional chemotherapy alone, and so there are no data that enable us to assess the efficacy of a molecular‐targeted agent as a monotherapy. </p> </section> <section id="CD011461-sec-0084"> <h3 class="title" id="CD011461-sec-0084">Quality of the evidence</h3> <p>See <a href="./full#CD011461-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>The risk of bias in the 11 RCTs varied according to the outcome of interest. The blinding procedures for five double‐blinded RCTs were well‐documented and at low risk of bias (<a href="./references#CD011461-bbs2-0002" title="EatockMM , TebbuttNC , BamptonCL , StricklandAH , Valladares‐AyerbesM , Swieboda‐SadlejA , et al. Phase II randomized, double‐blind, placebo‐controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro‐oesophageal cancer. Annals of Oncology2013;24(3):710‐8. ">Eatock 2013</a>; <a href="./references#CD011461-bbs2-0003" title="HechtJR , BangY , QinS , ChungH , XuJ , ParkJ , et al. Lapatinib in combination with capecitabine plusoxaliplatin in HER2‐positive advanced ormetastatic gastric, esophageal, orgastroesophageal adenocarcinoma: the TRIO‐013/LOGiC trial. Journal of Clinical Oncology2013;31(Suppl):abstr LBA4001. ">Hecht 2013</a>; <a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>). However, we noted that for three of them, sponsors were heavily involved in the data analysis/interpretation and manuscript preparation stages (<a href="./references#CD011461-bbs2-0004" title="DoshiS , GisleskogPO , ZhangY , ZhuM , OlinerKS , LohE , et al. Rilotumumab exposure‐response relationship in patients with advanced or metastatic gastric cancer. Clinical Cancer Research Published Online First: February 24, 2015. [DOI: 10.1158/1078‐0432] IvesonT , DonehowerRC , DavidenkoI , TjulandinS , DeptalaA , HarrisonM , et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first‐line treatment for gastric or oesophagogastric junction adenocarcinoma: an open‐label, dose de‐escalation phase 1b study and a double‐blind, randomised phase 2study. Lancet Oncology2014;15(9):1007‐18. ">Iveson 2014</a>; <a href="./references#CD011461-bbs2-0007" title="OhtsuA , ShahMA , VanCutsemE , RhaSY , SawakiA , ParkSRl , et al. Bevacizumab in combination with chemotherapy as first‐line therapy in advanced gastric cancer: a randomized, double‐blind, placebo‐controlled phase III study. Journal of Clinical Oncology2011;29(30):3968‐76. ShahM , KangY , OhtsuA , DelmarP , FoernzlerD , LangerB , et al. Tumor and blood plasma biomarker analyses in the avagast phase III randomized study of first line bevacizumab 1 capecitabine/cisplatin in patients with advanced gastric cancer. Annals of Oncology2010;21:viii67‐viii68. ">Ohtsu 2011</a>; <a href="./references#CD011461-bbs2-0009" title="ShenL , LiJ , XuJ , PanH , DaiG , QinS , et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double‐blind, phase III study (AVATAR study). Gastric Cancer2015;18(1):168‐76. ">Shen 2015</a>). The effect of this was hard to assess, but the consistent results observed through sensitivity analysis provide some indirect evidence that the involvement of study sponsors did not seriously undermine the findings of our review. The other six trials were at high risk of bias (<a href="./references#CD011461-bbs2-0001" title="BangYJ , VanCutsemE , FeyereislovaA , ChungHC , ShenL , SawakiA , et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet2010;376(9742):687‐97. FukudaT , ShimozumaK . Cost‐effectiveness analysis of trastuzumab to treat HER2‐positive advanced gastric cancer based on the randomised ToGA trial.. British Journal of Cancer2011;105(9):1273‐8. YeM , ChenH , ShenJF . Costs of trastuzumab in combination with chemotherapy for HER2‐positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clinical Therapeutics2012;34(2):468‐79. ">Bang 2010</a>; <a href="./references#CD011461-bbs2-0005" title="KoizumiW , YamaguchiK , HosakaH , TakinishiY , NakayamaN , HaraT , et al. Randomised phase II study of S‐1/cisplatin plus TSU‐68 vs S‐1/cisplatin in patients with advanced gastric cancer. British Journal of Cancer2013;109(8):2079‐86. ">Koizumi 2013</a>; <a href="./references#CD011461-bbs2-0006" title="LordickF , KangYK , ChungHC , SalmanP , OhSC , BodokyG , et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):490‐9. ">Lordick 2013</a>; <a href="./references#CD011461-bbs2-0008" title="RaoS , StarlingN , CunninghamD , SumpterK , GilliganD , RuhstallerT , et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first‐line treatment in patients with advanced oesophago‐gastric cancer: a randomised, multicentre open‐label phase II study. Annals of Oncology2010;21(11):2213‐9. ">Rao 2010</a>; <a href="./references#CD011461-bbs2-0010" title="WaddellT , ChauI , CunninghamD , GonzalezD , OkinesAF , OkinesC , et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncology2013;14(6):481‐9. ">Waddell 2013</a>; <a href="./references#CD011461-bbs2-0011" title="ZhangZD , KongY , YangW , ZhangB , ZhangYL , MaEM , et al. Clinical evaluation of cetuximab combined with an S‐1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World Journal of Surgical Oncology2014;12(1):115‐21. ">Zhang 2014</a>), mainly because of their open‐label design. </p> <p>We could not account for the inconsistency between individual trial results by our predefined subgroups. Although we expected variation in the results across the studies, we found that within subgroups heterogeneity remained high. Sensitivity analyses by risk of bias tended not to change the size or precision of the average effect but it did seem to reduce the amount of between‐study heterogeneity, implying methodological diversity as a possible explanation for the heterogeneity of our results. </p> <p>We downgraded the quality of evidence for survival outcomes and overall response, due to imprecision indicated by wide confidence intervals, and for quality of life, due to the small sample size of the only study which provided data for this outcome. Selective reporting of adverse events prompted us to downgrade the quality of evidence for this outcome, since minor adverse events were ignored in some reports, while others provided no summary data. </p> </section> <section id="CD011461-sec-0085"> <h3 class="title" id="CD011461-sec-0085">Potential biases in the review process</h3> <p>In order to include as many participants as possible, we decided to conduct combined primary analyses using data from all included studies that applied agents targeting different molecules, irrespective of different participant selection procedures. Between‐study heterogeneity due to clinical diversity was therefore highly probable. We subsequently performed subgroup analyses to accommodate this possible diversity, but they provided little explanation for the high level of heterogeneity detected. The unexplained inconsistency between individual trial results undermines the reliability of our efficacy assessment, and the random‐effects model we used to incorporate the heterogeneity further reduced the accuracy of the estimated effect size. </p> <p>To prevent bias in the review procedure, we used search strategies guided and developed by the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group. There were no restrictions (e.g. on language, publication type) on the search. Two review authors independently conducted study selection, assessment of the risks of bias, and data collection without blinding. We resolved any disagreements through discussion with a third review author. We dealt with missing information and data by repeated attempts to contact the authors. For studies that had only been published as abstracts, we tried to obtain further details by emailing the authors. Nevertheless, since we did not receive any replies from them, we failed to get enough information to assess the eligibility of two studies (<a href="./references#CD011461-bbs2-0020" title="WahabMA , EzzelarabL , ElBendaryS . Cetuximab plus capecitabine and oxaloplatin for chemonaive patients with advanced gastric cancer. Annals of Oncology2011;22:v50. ">Wahab 2011</a>; <a href="./references#CD011461-bbs2-0021" title="WangJW , ChiY , ZhengZX , QuT , ZhouAP , YangL , et al. Randomized, single‐centered, phase II clinical trial of nimotuzumab plus cisplatin and S‐1 as first‐line therapy in patients with advanced gastric cancer. Journal of Clinical Oncology2012;30(Suppl; abstr):e14668. ">Wang 2012</a>). For some outcomes (e.g. adverse events), we extracted only the data available from the study reports, and pooled them for our meta‐analysis. This incomplete study assessment and data pooling could produce bias, which may have influenced the precision and reliability of our results. </p> <p>In the <a href="#CD011461-sec-0103">Differences between protocol and review</a> section, we state that, since some relevant studies involved participants with esophageal adenocarcinoma, we subsequently broadened our criteria of eligible participants. Such post‐protocol change could have some potential impact on our findings. </p> </section> <section id="CD011461-sec-0086"> <h3 class="title" id="CD011461-sec-0086">Agreements and disagreements with other studies or reviews</h3> <p>The benefit of molecular‐targeted therapy for advance gastric cancer in prolonging survival time has been tested in clinical trials during these years. One review (<a href="./references#CD011461-bbs2-0070" title="WagnerAD , MoehlerM . Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Current Opinion in Oncology2009;21(4):381‐5. ">Wagner 2009</a>) found only limited data from Phase I and II studies, with results indicating modest benefits of targeted therapy in the participant population. Another review published four years later (<a href="./references#CD011461-bbs2-0049" title="KimJG . Molecular targeted therapy for advanced gastric cancer. Korean Journal of Internal Medicine2013;28(2):149‐55. ">Kim 2013</a>) summarized emerging data from more recent trials (without pooling the data), but also failed to find any conclusive evidence. However, both of these reviews, consistent with our results, emphasized a possibility of survival improvement among selected participants who were identified by molecular predictive and prognostic markers (e.g. HER‐2). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011461-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Schematic diagram of key signaling pathways in gastric carcinogenesis and the corresponding molecular targeted agents" data-id="CD011461-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Schematic diagram of key signaling pathways in gastric carcinogenesis and the corresponding molecular targeted agents </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study Flow diagram for RCTs" data-id="CD011461-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study Flow diagram for RCTs</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011461-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: main analyses, outcome: 1.1 Overall survival." data-id="CD011461-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: main analyses, outcome: 1.1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: main analyses, outcome: 1.2 Progression‐free survival." data-id="CD011461-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: main analyses, outcome: 1.2 Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: main analyses, outcome: 1.3 Overall response rate." data-id="CD011461-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: main analyses, outcome: 1.3 Overall response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Main analyses, Outcome 1 Overall survival." data-id="CD011461-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Main analyses, Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#CD011461-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Main analyses, Outcome 2 Progression‐free survival." data-id="CD011461-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Main analyses, Outcome 2 Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#CD011461-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Main analyses, Outcome 3 Overall response rate." data-id="CD011461-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Main analyses, Outcome 3 Overall response rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#CD011461-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Main analyses, Outcome 4 Quality of life, measured by EORTC QOL30 global health status scale (score changes between baseline and after treatment)." data-id="CD011461-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Main analyses, Outcome 4 Quality of life, measured by EORTC QOL30 global health status scale (score changes between baseline and after treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#CD011461-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Main analyses, Outcome 5 Adverse event (any)." data-id="CD011461-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Main analyses, Outcome 5 Adverse event (any). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#CD011461-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Main analyses, Outcome 6 Severe adverse event (≥ grade 3)." data-id="CD011461-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Main analyses, Outcome 6 Severe adverse event (≥ grade 3). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#CD011461-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Subgroup analysis according to the type of molecular‐targeted agents, Outcome 1 Overall survival." data-id="CD011461-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Subgroup analysis according to the type of molecular‐targeted agents, Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#CD011461-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Subgroup analysis according to the type of molecular‐targeted agents, Outcome 2 Progression‐free survival." data-id="CD011461-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Subgroup analysis according to the type of molecular‐targeted agents, Outcome 2 Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#CD011461-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Subgroup analysis according to specific molecular prognostic biomarker for participant selection, Outcome 1 Overall survival." data-id="CD011461-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Subgroup analysis according to specific molecular prognostic biomarker for participant selection, Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#CD011461-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011461-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/urn:x-wiley:14651858:media:CD011461:CD011461-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_t/tCD011461-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Subgroup analysis according to specific molecular prognostic biomarker for participant selection, Outcome 2 Progression‐free survival." data-id="CD011461-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Subgroup analysis according to specific molecular prognostic biomarker for participant selection, Outcome 2 Progression‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#CD011461-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/media/CDSR/CD011461/image_n/nCD011461-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011461-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: Molecular‐targeted therapy plus chemotherapy compared to chemotherapy alone for people with advanced gastric cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Molecular‐targeted therapy plus chemotherapy compared to chemotherapy alone for people with advanced gastric cancer </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with advanced gastric cancer<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> molecular‐targeted therapy plus chemotherapy<br/> <b>Comparison:</b> chemotherapy alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with chemotherapy alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with molecular‐target therapy plus chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population:12 month mortality rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.92</b> <br/> <b>(0.80 to 1.05)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3843 participants</p> <p>(10 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Assumed risk calculated based on 12 months overall mortality rates (extracted from corresponding Kaplan‐Meier curves) observed in the control arms of the included trials (53.6%). </p> <p>We could not explain variation in the effect by subgroup analyses examining the type of molecular targeted agent or tumour type. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>536 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>507 per 1000<br/> (459 to 553) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population: 6 month progression‐free survival rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.90</b> <br/> <b>(0.78 to 1.04)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4014 participants</p> <p>(11 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Assumed risk calculated based on 6‐month progression rate (extracted from corresponding Kaplan‐Meier curves) observed in the control arms of the included trials (55.5%) </p> <p>We could not explain variation in the effect by subgroup analyses examining the type of molecular targeted agent or tumour type. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>555 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>517 per 1000<br/> (432 to 577) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> (change from baseline in EORTC QOL30 global health status scale) </p> <p>Duration of follow‐up: Median follow‐up differed between treatment groups (28 months with molecular‐targeted therapy and 23 months in control group) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Higher change scores were obtained for chemotherapy‐alone group (MD 10 ± 33.9 SD) than molecular‐targeted therapy plus chemotherapy group (MD 0.0 ± 28.1 SD), but the results are based on a very small number of participants and the confidence interval is wide </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 participants</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>5,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall response rate</b> </p> <p>Duration of follow‐up: varied considerably between studies (the median follow‐up time ranged from 5.3 months to 28.5 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.24</b> <br/> <b>(1.00 to 1.55)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3723<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>365 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>417 per 1000<br/> (365 to 472) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse event (any)</b> </p> <p>Duration of follow‐up: varied considerably between studies (the median follow‐up time ranged from 5.3 months to 28.5 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 2.23</b> <br/> <b>(1.27 to 3.92)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2290<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>962 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>983 per 1000<br/> (971 to 990) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Severe adverse event (grade ≥ 3 )</b> </p> <p>Duration of follow‐up: varied considerably between studies (the median follow‐up time ranged from 5.3 months to 28.5 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.19</b> <br/> <b>(1.03 to 1.37)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3800<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>669 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>707 per 1000<br/> (676 to 735) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; <b>HR</b>: Hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to imprecision: the confidence interval obtained under both the primary and sensitivity analysis for risk of bias includes potentially meaningful differences with either intervention. </p> <p><sup>2</sup>Downgraded one level due to inconsistency: The size and direction of effect varied across the studies (significant heterogeneity was detected). </p> <p><sup>3</sup>Removal of studies at high risk of performance bias reduced the statistical heterogeneity and increased the effect size, so we did not downgrade for risk of bias. </p> <p><sup>4</sup>Downgraded one level due to imprecision: the confidence interval around the effect includes both meaningful benefit and little or no effect of molecular‐targeted therapy. </p> <p><sup>5</sup>Downgraded two levels due to imprecision: effect was estimated based on results from 53 participants and the confidence interval includes appreciable harm and little/no effect. </p> <p><sup>6</sup>Downgraded one level due to serious risk of bias: open‐label study was at high risk of performance bias for this outcome. </p> <p><sup>7</sup>Downgraded one level due to risk of bias (selective reporting bias): three included studies did not provide data on this outcome, and three others had no summary data for meta‐analysis. </p> <p><sup>8</sup>Downgraded one level due to risk of bias (performance bias): removing studies at high risk bias due to lack of blinding resulted in a more imprecise effect suggesting that the results may have been sensitive to the exclusion of open‐label studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: Molecular‐targeted therapy plus chemotherapy compared to chemotherapy alone for people with advanced gastric cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011461-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Molecular‐targeted agents for advanced gastric cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Molecular target</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Mechanism of action</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Targeted agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase of development</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>EGFR‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p>Anti‐EGFR mAb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cetuximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Panitumumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p>EGFR TKIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erlotinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gefitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Anti‐HER‐2 mAb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trastuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>HER‐2 and EGFR TKI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lapatinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>VEGF‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Anti‐VEGF mAb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Anti‐VEGFR mAb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ramucirumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>VEGFR TKI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MTI, targeted on VEGFR, PDGFR and Raf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sorafenib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MTI, targeted on VEGFR, PDGFR and c‐Kit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cediranib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mainly targeted on VEGFR‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apatinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P13K/mTOR‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>mTOR inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>HGF/MET‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p>MET TKI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Foretinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I‐II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crizotinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I‐II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>anti‐MET antibody</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Onartuzumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>anti‐HGF antibody</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rilotumumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMP‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>MMP inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Marimastat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>FGF‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>FGFR inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZD 4547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>dual inhibitor of FGF and VEGF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brivanib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HDAC‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>HDAC inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vorinostat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I‐II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EpCAM‐targeting agent</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Trifuctional bispecific antibody</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Catumaxomab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>EGFR: epidermal growth factor receptor; FGF: fibroblast growth factor; FGFR: fibroblast growth factor receptor; HDAC: histone deacetylase; HGF: hepatocyte growth factor; mAb: monoclonal antibodies; MMP: matrix metalloproteinase; MTI: multi‐targeted TKI; mTOR: mammalian target of rapamycin; PDGFR: platelet derived growth factor receptor; TKI: tyrosine kinase inhibitor; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Molecular‐targeted agents for advanced gastric cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/full#CD011461-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011461-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Main analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.80, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Overall response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.00, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of life, measured by EORTC QOL30 global health status scale (score changes between baseline and after treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse event (any) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.27, 3.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Severe adverse event (≥ grade 3) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.03, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Main analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#CD011461-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011461-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Subgroup analysis according to the type of molecular‐targeted agents</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 EGFR targeting agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.77, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 VEGF targeting agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.76, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 EGFR targeting agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.76, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 VEGF targeting agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.71, 1.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Subgroup analysis according to the type of molecular‐targeted agents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#CD011461-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011461-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Subgroup analysis according to specific molecular prognostic biomarker for participant selection</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Participants without biomarker selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.82, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Participants with HER2‐positive tumor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.63, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Participants with EGFR‐positive tumor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.61, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Participants without biomarker selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Participants with HER2‐positive tumor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.63, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Participants with EGFR‐positive tumor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.63, 2.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Molecular‐targeted therapy plus chemotherapy versus chemotherapy alone: Subgroup analysis according to specific molecular prognostic biomarker for participant selection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011461.pub2/references#CD011461-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011461.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011461-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011461-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011461-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD011461-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD011461-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011461-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011461\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011461\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011461\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011461\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011461\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=f00EizoA&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011461.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011461.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011461.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011461.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011461.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727855129"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011461.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727855132"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011461.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb64059c49368',t:'MTc0MDcyNzg1NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 